corporate responsibility report alongside interventions effective vaccine could really help reduce burden malaria africagsk corporate responsibility report gsk mission gsks mission improve quality human life enabling people feel better live longer developing innovative products improving access healthcare patients around world cover image nahya salim paediatrician research scientist tanzania africa working gsks rtss malaria vaccine trials ifakara health institute since currently overseeing trials new vaccine well researching malaria interacts diseases intestinal worms tb hiv guide use report interactive pdf designed help easily guide navigation buttons dynamic links full screen mode navigate report find information click dynamic links access relevant pdf set view full screen mode exit full looking go main contents information within report online use tabs screen mode press escape view full toolbar top navigate sections search pdf printerfriendly pdf overview summary use print icon navigation print print overview pages beginning section whole document printfriendly format go preceding provide highlevel summary approach performance also download summary go next report go overview sections summary return last visitedgsk corporate responsibility report contents inside report approach health behaviour people planet governance engagement learn find read learn create find find developing innovative embedding values inspiring supportive managing manage corporate ensure business products improving throughout business work environment environmental impacts responsibility engage operates responsibly access healthcare including ways encourages employees operations products stakeholders identify patients around world research develop sell develop capabilities across life cycle material issues report market products achieve best reduce carbon emissions progress water use waste glance health overview behaviour overview people overview planet overview governance engagement improving healthcare putting patients first setting standard taking scientific report chairmans statement global challenge sales marketing employee healthcare approach sustainability ceos statement groundbreaking partnership values principles talent leadership carbon create value save children research practices development water business strategy innovative science working healthcare inclusion diversity waste commitments create value professionals engaging people managing impacts access healthcare sales marketing health safety wellbeing engagement diseases manufacturing supply performance reward data summary developing world public policy recognition summary hivaids patient advocacy assurance statement health wellbeing approach tax communitiesnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report glance part commitment transparency report performance year across four areas responsible business approach health behaviour behaviour external recognition achieved major milestone announced plans evolve way became first pharmaceutical malaria vaccine candidate rtss sell market products company enable external topped biannual demonstrated months healthcare professionals researchers access detailed access medicines index followup almost halved number align companys activities anonymised patientlevel since began malaria cases young children aged interests patients data clinical trials next index months first vaccination new online system reduced around quarter malaria see healthcare cases infants aged weeks first see company included vaccination cdp performance see leadership index planet cdp disclosure leadership index scope carbon emissions people operations grew slightly launched new performance although remain lower became first company management system benchmark awarded global certification better link employee carbon trusts water scope emissions excluding raw reward values standard recognition materials increased reducing water health year year yearonyear across value chain due strong sales formed innovative new partnership see hfa propellantbased inhalers reductions operational water use globally save children help save increased since lives one million children five years achieved bronze ranking see see robecosams sustainability yearbook based submission putting us top health people planet industry donated four billionth albendazole began roll preventive used less water tablet fight lymphatic filariasis healthcare benefits operations member ftsegood intestinal worms part commitment partnership prevention programme using less since work partners control eliminate available employees ten neglected tropical diseases families worldwide see bn see narrowly missed inclusion dow jones sustainability ranking see score note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report gsk scienceled global healthcare company researches manufactures range products help people feel better live longer global healthcare company pharmaceuticals vaccines consumer healthcare commercial success depends creating innovative new medicines vaccines healthcare products making accessible many people need possible able grow business provide benefits patients consumers society employees shareholders put values heart every bn bn bn decision make commit help people feel better live longer turnover group turnover group turnover group develop make medicines treat vaccines business one largest develop market range broad range conditions including world producing vaccines consumer health products based respiratory disease cancer heart disease children adults range scientific innovation brands four bacterial viral infections hiv infectious diseases delivered main categories total wellness oral care lupus skin conditions million vaccine doses nutrition skin health use developing countries values employees region turnover region transparency respect significant global commercial bn people integrity presence markets network manufacturing sites patient focus worldwide rd centres uk usa group turnover spain belgium china usa usa europe europe emap emap japan japan othernote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report chairmans statement chairman board boardlevel corporate responsibility committee see firsthand gsk responsible business message chairman demonstrating robust governance central companys strategy importance strong ethical behaviour committee continues recognise operating according companys value external perspectives bring values something board may sophia tickell reappointed colleagues pay continued attention external advisor respected cr expert specific expertise healthcare allegations fraudulent behaviour climate change brings valuable certain employees within business external insight would also like welcome china wholly contrary companys nonexecutive director hans wijers values take matter extremely joined committee october seriously addition chinese government investigation cr committee board company continues deliver strong commissioned independent review continue support constructively operational financial performance chinese operations law firm challenge companys actions doubt commercial ropes gray implement operate responsible valuesbased success directly linked operating appropriate actions necessary business look forward seeing responsible way meets conclusion investigations progress changing expectations society role cr committee provide respect company continues highlevel guidance oversight adopt industryleading positions matters related responsible business range issues reviewed progress announcement plans ambitious cr commitments first set evolve way business interacts last years report one year healthcare professionals pays longterm goals sales staff developments close completion indeed sir christopher gent particularly pleased see would question whether chairman challenging enough committees way board strongly view gsk track supports commitments company tangible evidence steps taken made advance transparency around help company achieve clinical trial data time see hoped steps advance medical science improve patient carenote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report ceos statement global healthcare company gsk play important role meeting societal challenges continued develop innovative lifesaving drugs message ceo work partners get medicines people need made new commitments donated four billionth tablet continued commitment transparency increase transparency clinical albendazole treat intestinal worms also evident efforts disclose research announcing support lymphatic filariasis part longterm address environmental impacts alltrials campaign becoming first commitment tackle neglected tropical healthcare company listed pharmaceutical company commit diseases delivered million vaccine cdps disclosure leadership publishing detailed clinical study reports doses worldwide also strengthened index performance leadership index medicines may global initiatives tackle noncommunicable clear reporting first industry launch online diseases cancer diabetes performance climate impacts system enabling researchers request respiratory heart disease job ceo deliver healthy access anonymised patientlevel data also delighted achieved company possible clinical trials pleased past six years significant milestone malaria vaccine healthy employees ground breaking companies also making fundamental changes deliver candidate demonstrated could partnership prevention initiative give adopted approach innovation access products potentially halve number malaria benefitseligible employees patients customers improved also announced plans evolve way cases young children vaccine families equal access preventive sustainable financial performance sell market products healthcare potential save hundreds thousands basic healthcare benefits wherever shareholders professionals align activities childrens lives plan file based interests patients remove approval committed productive period continue challenge even perception conflict interest making available notforprofit price rd output companys history business model every level ensure specifically plan stop direct six major new medicine files profiled higher priority responding needs patients payments healthcare professionals start five approved valuesbased conduct employees meeting wider expectations society speaking engagements attendance expecting regulatory decisions past years focused medical conferences extend us remaining asset group first bringing life values patient first programme globally half addition launched thoughtful really mean decouple sales team remuneration new injectable quadrivalent flu vaccine human level scrip generation usa together new drugs offer strong belief patients range new treatment options continue expand access companys values allegations made represent substantial opportunities medicines people living china behaviour business growth developing world sir andrew witty individuals disappointing chief executive officer continue take action reform signed groundbreaking investigation matter business model meet expectations fiveyear partnership save children authorities china continues society deliver mission line combine resources capabilities cooperating fully company values two organisations help save committed learning lessons lives one million children living taking necessary action relation poorest countries africa outcome investigationnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report create value adapting business model pursuing strategy delivers sustainable performance innovation expanding access driven values mission strategic priorities grow deliver business model outputs challenging inspiring simplify help us work towards vision broadlybased balanced delivering innovation maximising mission improve quality human life enhancing business performance business across pharmaceuticals vaccines access products generates value enabling people feel better delivering sustainable growth consumer healthcare core patients society widely live longer mission gives us business model concepts innovation focus understanding needs primary contribution make purpose develop innovative medicines access create value researching patients consumers individual markets products provide benefits patients products make available manufacturing innovative high channel research consumers many people need possible quality products making developing appropriate products accessible many people need successful delivery generates mission underpinned number insights also enable us adapt possible profitable sustainable performance key factors business model improve availability turn allows us generate value affordability improving healthcare making achieve mission rely returns shareholders affordable accessible people people knowledge expertise enables us reinvest business huge challenge one requires enthusiasm put values combined effort also create value making direct heart every decision make indirect economic social meet challenge everyone involved contributions countries providing healthcare industry healthcare operate wider benefits society mission business model outputs professionals universities healthcare include contributions tax funders including governments charities employment enhancing wellbeing regulators need work together local communities global improve quality rd benefits patients mind partnership community initiatives human life enabling customers collaboration key principle discovering people developing innovative business approach feel better live longer medicines cash profit continue reform business model underpinned generation example taken industryleading manufacturing values positions improve global public health making shipping pricing access strategies shareholder value high standard products increase transparency clinical trial strategic priorities around world returns data modernise commercial practices interactions customers people commercialisation wider benefits distribution society insights increasing access products reinvestmentnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report business business strategy aims help us deliver sustainable growth reduce risk enhance longterm value deliver shareholders society strategy aim progress highlights priorities bn grow creating total sales grew billion successful launch commercialisation balanced business product excluding divestments new products pipeline diversified portfolio capable delivering performance generated multiple continue invest key growth business sustainable sales growth businesses geographies reflecting group turnover businesses including emerging markets centred three business successful implementation strategy vaccines consumer healthcare areas pharmaceuticals look opportunities vaccines consumer healthcare increase focus optimise value group turnover outside usa europe product portfolio deliver changed rd received approvals six major delivery phase iii data six organisation better new products several new indications existing potential new medicines vaccines products able sustain pipeline products medicines vaccines around ten nme phase iii starts offer valuable improvements significant new product approvals across value treatment patients also generated high volume phase iii healthcare providers data key assets pipeline continued focus increasing rd rate return estimated return rd investment underpinned focus increased improving productivity medicines phase iiiii development rates return rd simplify business continues change several restructuring programmes cost savings delivery shape transforming track deliver total annual savings restructuring programmes operating operate billion compared rollout standardised enterprise reduce complexity become delivered incremental savings incremental savings model platforms delivery integrated efficient million supply chain frees resources reinvest also making good progress transforming elsewhere business manufacturing network supply chain enterprisewide processes days reduction working capital responsible responsible business made considerable progress file rtss malaria vaccine candidate central strategy agenda operate responsibly approval approved business deliver success important offer notforprofit price specifically took action increase transparency achieve ensuring increase volume medicines supplied values embedded culture clinical research data modernise commercial least developed countries since implement changes operations interactions customers incentivise sales teams decisionmaking helps us better st work healthcare professionals meet expectations society also made progress driving access medicines poorest countries passed key milestone development potential vaccine malaria pharmaceutical company sign alltrials campaign research transparencynote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report commitments developed forwardlooking commitments across four areas responsible business approach aim address unmet global health needs progress overview aligned strategic priorities values year reporting progress commitments provide summary commitments progress tracker find lla rof htlaeh innovation unmet adapt open innovation rd model currently used diseases developing track worked promote rd new antibiotics accelerate development medical needs world apply areas great unmet medical need scientific challenge treatments alzheimers disease innovative medicines including infectious disease alzheimers disease initiative continued research multidrugresistant tuberculosis developing vaccines invest development vaccines dont require continuous refrigeration track partnered bill melinda gates foundation accelerate dont need making distribution easier less expensive advances vaccine research including making less vulnerable kept cold heat building products continue build core range products formats better meet needs track catchup programme developing countries received approvals better meet needs people across globe including less able access afford products products reached villages india low cost nutritional formulation horlicks better access embed flexible pricing strategy innovative business models progressing well updated approach tiered pricing vaccines medicines prescription medicines vaccines increase usage among less able vaccines access afford products reducing child mortality continue invest innovative crosssector partnerships reduce child mortality track formed groundbreaking partnership save children help save one million childrens lives strengthening healthcare continue work partners support development strengthening progressing well launched innovative partnerships barclays vodafone infrastructure healthcare infrastructure anticipate could improve access healthcare invested million strengthening healthcare infrastructures million underserved people vs reinvestment programme least developed countries access antiretroviral viiv healthcare continue increase access medicines care track committed grant unsupported medicines patent pool treatment hiv adults children living hiv around world help world health voluntary licence develop paediatric formulations antiretroviral organization unaids achieve goal reaching million people medicine abacavir treat hiv countries hiv globally antiretroviral treatment positive children live globally fighting malaria build year commitment contribute fight malaria progressing well announced large scale phase iii trial data malaria vaccine rtss continued rd investment partnerships ground developing medicine tafenoquine partnership mmv treatment relapse prevention vivax malaria eliminating help eliminate control ten neglected tropical diseases affect billion track donated million albendazole tablets eliminate lymphatic filariasis controlling neglected people including elimination lymphatic filariasis control soiltransmitted helminths screened compound tropical diseases continued investment rd ongoing product donations contribution library promising treatments parasites cause sleeping london declaration neglected tropical diseases sickness chagas disease visceral leishmaniasis eradicating polio continue support objective eradicating polio providing progressing well provided million doses oral polio vaccine global vaccines unicef achieved polio eradication initiative note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report commitments progress tracker find ruoivaheb ruo promoting values sales continue drive valuesbased approach sales marketing practices across track announced changes global sales marketing practices marketing practices world interests consumers patients core ensure patient interests come first introduced new performance management system focused values rigorous patient continue ensure interests safety patients consumers progressing well strengthened resources enhance pharmocovigilance operating consumer safety paramount importance way design undertake clinical trials model expanded dedicated product quality teams maintained product quality assurance monitoring reporting adverse events robust policies governance framework patient safety ongoing product usage minimising animal testing rigorously challenge need animal studies work minimise impact track reduced number animals used research animal welfare investing development alternative studies sharing animalbased data promoting human rights address un guiding principles business human rights across track conducted human rights impact assessment prioritised seven operations supplier relationships areas analysis updated human rights statement accordingly transparency clinical transparent possible clinical trial data including publishing progressing well launched online system enabling researchers request access trial data clinical study reports without patientlevel data outcome trials medicines detailed anonymised patientlevel data clinical trials conducted gsk within appropriate process making available became first pharmaceutical company publish clinical study reports researchers access anonymised patient level data scientific enquiry ensuring ethical demonstrate gsk interactions patient advocacy groups political track embedded new criteria ensure public policy groups work stakeholder interactions stakeholders conducted appropriately ethically transparently aligned values agreed relevant standard operating procedures elpoep ruo promoting inclusion continue promote inclusion diversity globally gsk track agreed establish global disability council introduced gender diversity targeted coaching sponsorship creating inspiring continue create working environment inspires people grow perform track interim employee survey results showed improvements team leader healthy workplaces healthy resilient way effectiveness continued roll preventive healthcare employees reduced injury illness rates community volunteering extend volunteering opportunities bring positive change communities track increased number employees taking part pulse volunteer create change global health providing individual development partnership programme tenalp ruo commitments progress overview continued aiming reduce overall carbon footprint vs carbon work scope carbon emissions operations carbon neutral neutral value chain since scope emissions excluding raw materials since due strong sales hfa propellantbased inhalers reducing reduce water impact across value chain vs track used less water operations vs mapped water use water impact across value chain became first company awarded global certification carbon trusts water standard reducing reduce operational waste vs track cut total waste sent less landfill vs achieved waste zero waste landfill sites building sustainability build sustainable supply lines nutrition portfolio work local farmers track began working dairy supplier india develop secure supply supply chain improve agricultural practices improve yields competitiveness locally produced whey protein milk make horlicks livelihoods source whey protein local supplier india horlicksnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report health focus driven steadfast focus patient bringing health benefits people around world philomene treated breast cancer butaro cancer centre open flexible excellence rwanda part work address noncommunicable collaborative approach innovation diseases developing world funding training cancer access healthcare healthcare professionals rwanda partnership charities government increase access trained cancer specialists patients like philomene read section health overview improving healthcare global challenge groundbreaking partnership save children innovative science create value access healthcare diseases developing world hivaids health wellbeing communities note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report health overview bring new vaccines medicines external perspective external perspective patients faster accelerating innovation processes opening c ommunity health workers provide given scale disease research findings resources others bringing together partners explore vital services rural communities burden developing countries new delivery models flexible pricing gsk pioneer look forward continued strategies increase access existing trailblazer supporting work gsk develop essential range products internal perspective deployment chws across africa lifesaving health interventions forefront one million community health particularly excited transformation industrys approach cientific technological workers campaign save lives gsks longterm commitment global healthcare past decade know still much innovation enable us make help rural communities global health rd innovation done meet major health challenges advances necessary bring subsaharan africa break free malaria want play leading role effort new medicines new ways extreme poverty promoting generating returns need dr trevor mundel invest grow business patients everywhere gsk systematic deployment million president global health programme working many partners chws roughly per bill melinda gates foundation remain committed improving across many areas gene households rural areas treatment options lifesaving vaccines medicines strategies therapy biopharmaceuticals campaign support subsaharan extend access foster innovation develop medicines diseases africa make major strides continued focus diseases effective treatments towards millennium developing world ways currently exist also playing development goals beyond evolved business model enable us part exploring new ways make significant contribution uns jeffrey sachs millennium development goals stimulate innovation areas director earth institute commercial incentive weaker sustainable development solutions network work collaboration others sector beyond example tb antibiotic creating sustainable solutions resistance alzheimers improve quality life enabling people feel better live longer patrick vallance president pharmaceuticals rd gsknote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report health glance innovative science create value access healthcare diseases developing world hivaids six major new medicines profiled increased focus noncommunicable achieved major milestone malaria obtained regulatory approval usa start five approved diseases diabetes cancer vaccine candidate demonstrated canada chile tivicay dolutegravir expecting regulatory decisions developing countries research months followup rtss almost new treatment option people living remaining asset first half training healthcare providers halved number malaria cases young hiv also launched new injectable children aged months first quadrivalent flu vaccine usa see vaccination reduced around see quarter malaria cases infants aged gsk accounted fda weeks first vaccination new drug approvals see see access healthcare partnered save children help save lives one million children innovative science create value diseases developing world hivaids see bn donated four billionth albendazole tablet agreed grant unitaidbacked fight lymphatic filariasis intestinal medicines patent pool voluntary access healthcare worms part commitment work licence paediatric formulations invested bn global research delivered million vaccine doses partners control eliminate antiretroviral medicine development innovative medicines gavi alliance affordable prices protect neglected tropical diseases abacavir countries vaccines consumer products children pneumococcal diseases see w chh ie ldr e n li hiv positive rotavirus gastroenteritis cervical cancer new molecular entities bn phase iiiii clinical development see see see access healthcare access healthcare diseases developing world health wellbeing communities updated tiered pricing model reinvested provided million doses oral polio vaccines increase support countries profits made least vaccine part continued support committed longterm immunisation developed countries global efforts eliminate disease programmes reflects ability pay million train contributed billion doses community health workers since see strengthen healthcare donated million promote health infrastructure see wellbeing communities countries funding product donations employee volunteering see see note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report improving healthcare global healthcare company gsk works within context global health burden exemplified un millennium development goals global challenge recognise complex barriers health responding innovative ways gsks response treatments dont exist resistance existing diseases developing world neo er de e e df f fe oc r div ie etr ae sa et sm ie nn ct lus da ir ne g barriers rr ee sa sm tae nn ct es antimicrobials malaria antibiotic resistance working gates foundation tuberculosis hepatitis c problem many diseases committed tackling malaria world health organization developing take affecting developing countries vaccine research developing pharmaceutical companies donors years cost hundreds including malaria new treatments promoting use helping control eliminate millions pounds low preventive measures increasing neglected tropical diseases returns access antimalarials least affect billion people global health burden developed countries see see pages child mortality malaria h g esof igf pvo h e er r cd p n ira ami lcb le yei nl tit h sy c e n n p r p e iv lloe iopn nlt e l ving bt ii rix l tl hm dii e alli yo b n e fc eoh srei pl thr ee e n air fi fy e ha r e ac lah r iy aie l l ga ior lon bh ce aar ls le ye asr n e fa mro ou rn ed prt esig vc em ri nma pna aan ttd ii eo nn nc sdr ui fs ft ei g ria nm gt ai cn less day buying drop child mortality malaria diseases hiv medicines need since deaths even asthma occur countries accessing treatment pricing viiv healthcare cap prices patented specialist hiv company gsk jointly medicines vaccines least established pfizer developed countries offer flexible researches new treatments improves tiered pricing middle income countries maternal health hivaids access medicines works take responsible approach communities combat stigma pricing high income countries pregnant million people discrimination surrounding hivaids women developing living hiv see see countries receive million people poverty healthcare infrastructure recommended healthcare received antiretroviral poverty huge effect many developing countries lack pregnancy therapy low middle peoples health adequate healthcare facilities income countries wellbeing factors staff africa suffers lack resources global burden malnourishment unsafe water disease poor sanitation health workers contribute poor health tuberculosis non communicable despite drop diseases ncds tb mortality ncds account reinvestment tb still killed million twothirds global save children partnership since reinvested people deaths developing groundbreaking partnership profits generate least quarter countries carrying bringing much needed medicines developed countries programmes hivpositive half worlds vaccines worlds strengthen community healthcare ncd burden poorest children training thousands improve access healthcare healthcare workers seeking countries alleviate child malnutrition see see note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report groundbreaking partnership save children help save one million lives comprehensive interventions un commission see africa commitment joint rd board life saving commodities malaria partnership see continue invest innovative crosssector explore development also registering together partnerships reduce child mortality new repurposed products awarded us million childfriendly powderbased tackle causes healthcare antibiotic drc groundbreaking million grants newborn infant death innovations originating help fight pneumonia one partnership international encouraging employees developing world award one first lifesaving biggest killers children childrens charity save raise million year split five projects reformulation five well children help save volunteering organisations chlorhexidine antiseptic developing lowcost lives one million children fund raising see largest portion going found corsodyl nutritional product help combining expertise globally six million mouthwash umbilical combat child undernutrition friends sick children resources capabilities children die every year due cord cleansing prevent malawi development bring muchneeded lack basic healthcare infection newborns new partnership builds lowcost device help medicines vaccines vaccines nutritious food applied first days collaboration newborn infants breathe worlds poorest save children establishing life gel could play children train thousands past eight years signature programmes vital role preventing source httpwww healthcare workers seek democratic republic infection saving babies includes work everywomaneverychildorg alleviate child malnutrition reinvestment programme resourcesuncommissiononlife congo drc kenya lives one savingcommodities gsk investing least least developed countries test impact series interventions recommendednote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report innovative science approach innovation helping us strengthen portfolio medicines vaccines consumer healthcare products bring benefits patients around create value world committed creating innovative six major new medicines discovery performance unit dpu also encourage entrepreneurship products deliver value based discovery research strategy also innovation biotech sector breorelvar ellipta approved usa healthcare payers providers continuing progress well example joined forces johnson treat chronic obstructive pulmonary patients accelerating shown sustained improvement quality johnson launch index ventures disease copd fifth leading cause delivery new products streamlining compounds especially first fund dedicated making death globally europe treat research development rd focusing research areas prospected investments life sciences sector asthma copd japan treat products bring value immunoinflammation antibody platforms independent corporate venture asthma forging strong partnerships others epigenetics heart failure firm sr one gsk also founding industry academia anoro ellipta also approved copd investor new global health committing resources stimulate investment fund see case study usa also aim stimulate innovation innovation development promising opening access expertise tafinlar oral metastatic melanoma new technologies could treat facilities cases intellectual diseases tomorrow example therapy approved usa europe property support external research established new bioelectronics rd areas great medical need mekinist treatment melanoma unit catalyse research approaches approved usa modulate signalling patterns developing medicines vaccines nerves specific organs offer new diseases disproportionately affect tivicay viiv healthcares new treatment ways treat chronic diseases developing countries poorer option people living hiv approved populations middleincome countries usa europe remains key focus gsk saving millions lives hows return investment fluarixflulaval quadrivalent flu vaccines unprecedented approvals protect four different strains strong pipeline virus approved usa committed us million new mitigate risk investing clinical approach helping us accelerate rd flulaval europe fluarix investment fund structured jpmorgan development new technologies gates chase co bill melinda gates foundation swedish international yielding impressive results six major pipeline remains extensive foundation help tackle health challenges development cooperation agency partially new medicine files profiled start aim continued flow product particularly prevalent lowincome offset potential losses fund gsk five approved breo anoro launches bring benefits countries advancing promising also contribute valuable advice scientific respiratory disease tafinlar mekinist innovations global health investment product development manufacturing patients continue diversify melanoma skin cancer tivicay hiv fund ghif finance development regulatory issues participation portfolio around new molecular expecting regulatory decisions new drugs vaccines diagnostic tools funds scientific advisory board entities nmes phase iiiii clinical albiglutide remaining asset group interventions target malaria development expect first half addition launched tuberculosis hivaids maternal new injectable quadrivalent flu vaccine phase iii readouts six nmes infant mortality planning ten nme phase iii starts key usa overall gsk accounted areas respiratory oncology fda new drug approvals immunoinflammation achieved feat spending less rd five years agoskoorb nairdaivag note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report innovative science create value continued innovate patient seminars topics neglected foster innovation empower scientists tropical diseases type diabetes gene researchers think creatively therapy hiv chronic hand eczema maintaining focus scientific discipline duchenne muscular dystrophy help us effectively collaborating others research treatments offer worlds biggest public health challenges significant improvements existing solved researchers options based understanding different scientific organisations patient needs institutions work together sharing knowledge expertise end create smaller specialist research teams involved number innovative specialist multidisciplinary collaborations broad range discovery performance units public private bodies include simplify processes improve team initiatives governments scientific institutions companies address efficiency enable people focus key public health problems including higher value activities antibiotic resistance dementia access catalyse innovation collaborations public private making vaccines immune heat organisations identify terminate projects h aving world turned upside commitment gsk bmgf invest combined us million early stage research unlikely successful early free due systemic resources pursue promising leads invest development vaccines dont vaccine thermostability sclerosis diagnosis focus require continuous refrigeration making distribution focus progressing development patient programme given hope easier less expensive one first projects exploring pipeline projects optimising resources cure discovered make adjuvants critical component innovative smarter clinical vaccines notoriously susceptible vaccines heat stable consigning debilitating disease trial design heat making transport challenge project initially focus gsks rtss history books programme especially hot remote regions malaria vaccine candidate see focus patient provided perfect platform people often need designed use infants programme connect researchers patients ultimately share daytoday challenges children subsaharan africa gsk bill melinda gates developing medicines provides living condition highlight maintaining vaccines optimum foundation bmgf partnered new joint researchers important insights potential areas future treatments temperature challenging initiative aims accelerate advances challenges living disease currently absent vaccine research development enables us incorporate patient feedback directly rd process potential transform global health nicola whitehill employees participated seven focus patient participantnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report innovative science create value continued discovery partnerships academia targeting unmet medical needs programme brings together insight addressing urgent need tackle antibiotic resistance creativity academic world gsks commitment drug discovery expertise tools one would like go back time commitment license new adapt open innovation rd model currently used translate innovative research medicines penicillin revolutionised antibacterials agricultural use diseases developing world apply benefit patients launched areas great unmet medical need scientific treatment bacterial infections recognising high levels discovery fast track north america challenge including infectious disease alzheimers alarming growth antibiotic resistance antibacterial use farming competition designed identify promising disease making impossible scenario potential increase resistance academic research could accelerate probable adopt flexible business models also participating range development new therapies eight enable us use expertise address antibiotic resistance ability collaborations address challenges projects selected target important unmet areas unmet medical need microorganism withstand delivering new antibiotics market medical needs including antibiotics necessarily potential commercial effects antibiotic coincided including new drugs bad bugs resistance diseases developing world return central open innovation declining antibacterial drug development key programme innovative certain types cancer winners strategy transformed result world seeing isolated medicines initiative granted access gsks screening approach intellectual property infections multiresistant bacteria unprecedented initiative led technology compound libraries external partnerships untreatable existing drugs development three new collaborative expertise drug discovery current open innovation models despite challenging scientific models clinical trial basic research trust science partnership focus diseases developing world regulatory commercial environment drug discovery created single government funding agencies aims build also exploring ways extend one pharmaceutical vision comprehensive research plan sustainable longterm scientific research models solve pressing health companies committed delivering new fully collaborative framework base latin america africa challenges including antimicrobial antibacterials help address agreement takes account initiative partners gsk teams resistance noncommunicable diseases growing threat antibacterial resistance interest partners involved scientists develop medicines diseases alzheimers commitment includes one investigational affecting regions focusing infectious dedicated rd team focused antibacterials due enter phase iii diseases well noncommunicable example working others antibiotics research resulted development already diseases eleven new projects selected encourage research new antibiotics three antibacterial compounds seeing evidence approach support brazil argentina innovative medicines initiative imi early stages clinical trails antibiotics rd working potential addition existing active projects one largest publicprivate partnerships new medicine discovered gsk latin america also launched trust global health research see gsk endorsing appropriate use scientists developed science africa received also leading imis pharmacog project antibacterials aiming reduce resistance partnership usas defense threat proposals kenya tanzania uganda aims accelerate development new ensuring right medicine reduction agency biomedical eight selected areas drugs alzheimers disease prescribed right dose right advanced research development malaria hiv nutrition maternal health funding uk dementias research duration antibacterial stewardship authority highlighting merits copd platform led medical research collaboration area council platform publicprivate ongoing efforts engage scientific partnership seeks improve ability medical communities share detect signs earlystage findings rd neurodegenerative disease support development new treatmentsnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report innovative science create value continued early joined accelerated part commitment already open lab wellcome trust awarded medicines partnership amp new screened gsks entire compound library research open lab tres cantos additional million gsk take partnership national institutes two million compounds may spain focused discovering open approach step health nih ten pharmaceutical inhibit malaria tb identifying developing new medicines diseases enable researchers open lab companies three nonprofit promising hits respectively making developing world see tackle next phase drug development organisations goal amp information hits available hope generate direct projects aim turning promising active transform current model developing encourage scientists carry simply support ideas others compounds high quality experimental new diagnostics treatments additional research drive end visiting scientists drugs funding help progress challenging disease areas jointly discovery new treatments made use open lab working promising projects underway identifying validating promising diseases malaria compound set part early stage research alongside independent scientists open lab biological targets work begin three malaria box set medicines scientists utilising facilities gsks research portfolio disease areas alzheimers disease malaria ventures sent resources knowledge advance us national institutes health httpwwwnihgov diabetes autoimmune disorders groups around world also research projects since open lab newshealthjunncatshtm rheumatoid arthritis lupus initial shared tb compound set established built investment million gsk ten research groups around world portfolio research projects onethird participating providing open lab initiative researchers complete funding alzheimers pilot data also screening compound library analyses generated work hits could ultimately lead new made publicly available broad treatments neglected tropical diseases biomedical community see also working collaboration participated innovative pilot partners industry academia project led us national center enhance approaches delivering new advancing translational sciences enabling clinical candidates multidrug academic researchers evaluate compounds resistant tuberculosis tb released new therapeutic uses also partnered innocentive utilise sharing research global network problem solvers come industry average time discovery solutions key challenges approval new drug crowdsourcing example years failure rate solvers countries responded believe sharing research challenge explain unusual toxicity profile findings successes failures resulting credible proposals accelerate drug development two ultimately pursued process helping others build existing research stimulate innovation also enable independent researchers develop new therapies patients examine findings conduct analyses medical research see note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report access healthcare committed improving access products irrespective people live ability pay focusing affordability availability products investing strengthening health systems lack access healthcare acute also encourage governments adopt dcma unit adopts lower pricehigher immunisation programmes worlds poorest countries millions public policies support differential volume approach developing countries worlds poorest countries gavieligible people regions communities pricing instance continued employees incentivised increase countries gross national limited resources still cant access support eus tiered pricing volumes medicines delivered rather income per capita us healthcare need including vital regulation work uks focusing revenue bring always get lowest prices vaccines medicines diagnostics industry government forum access since unit established little onetenth medicines volume medicines supply ldcs developed countries approach improve access employ innovative increased million packs designed support governments making funding mechanisms use flexible pricing developing countries product longterm investment immunisation pricing approach based millions people resourcepoor reflects desire enable countries countrys wealth ability pay well settings affordability significant barrier since capped prices expand upon commitment working improve availability getting medicines need patented medicines ldcs immunisation economies grow products people need gsk commissioned first ever global prices charged developed even vaccines medicines study identify healthcare innovations countries provided cover g iving countries prices vaccines available arent always enough trained developing countries could manufacturing costs sustain health workers administer help replicated increase access affordable prices long term reflect ability pay enables address challenge helping medicine study conducted plan programmatically capped prices apply brands treat strengthen healthcare infrastructure international centre social franchising financially ultimately noncommunicable diseases particular focus training health workers assessed opportunities scale asthma copd well infectious create better predictability return replicate healthcare programmes affordability found part existing diseases malaria also vaccine companies able reduced prices offpatent healthcare delivery models target access wider markets increase commitment antibiotics augmentin zinnat affluent emerging middle class rather certain countries vaccines production volumes reduce poorest embed flexible pricing strategy capped west european manufacturing costs innovative business models prescription increasing overall volume products average price medicines vaccines increase usage among opportunity right thing less able access afford products sell able sustain lower prices vaccines included immunisation people need afford essential medicines vaccines innovative business models offer need developing campaigns countries worldwide vaccines today range options improve affordability countries market access dcma delivered million vaccine medicines vaccines including price operating unit clear objective doses use dr seth berkley caps poorest countries flexible increase patient access gsk medicines developing countries ceo gavi alliance tiered pricing middleincome countries vaccines around million people refined approach support governments low least developed countries ldcs vaccines pricing increasing number income patients highincome countries expanding market presence pricing tiers basing price ranges ensuring business continues used tiered pricing model gross national income per capita sustainable vaccines years enabling us lowest tier tier corresponds gavi produce reliably supply effective eligible countries gsk longstanding highquality vaccines support partner gavi alliance funds continuous development new vaccinesnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report access healthcare continued committed provide flexible pricing innovative payment managing healthcare costs highincome europe tailor approach specific additional million doses synflorix schemes enable people access countries country needs work governments gavi alliance use developing products growing business highincome countries also face challenges demonstrate value patients payers countries next ten years increasing volumes sell market related affordability healthcare healthcare professionals taxpayers help protect million access pricing team responsible public healthcare budgets europe industry example partner children pneumococcal diseases developing innovative pricing strategies immense pressure result italian government enable earlier patient meningitis pneumonia leading establishing market access programmes economic environment access innovative medicines sharing cause death children five make gsk medicines available many americans lacked health insurance risk responsibility managed developing countries addition patients possible countries coverage entry schemes include cost sharing million doses vaccine discounts price arzerra affordability remains barrier markets also take responsible already committed gavi leukaemia drug risk sharing discounts offer range payment schemes approach prices important advance market commitment framework price initial therapies non makes easier patients afford reflect value medicines bring offers heavily discounted vaccines responder patients payforperformance treatments need often patients also mindful children living worlds poorest votrient tyverb drugs fully partnering ngos include burden healthcare costs thats countries supplied million reimburses costs nonresponder patients pricing according patient income priced newly launched products doses vaccine introductory monthly payment plans help patients prices currently vaccine programmes four countries manage cost treatments available despite positively gsk also committed million doses discount cards enable eligible patients differentiated profiles source httpwwwhsphharvardedunewshsphinthe newsglobalhealthnoncommunicablediseasesbloom rotarix gavi next five years receive direct discounts picking help protect million children prescriptions partner rotavirus gastroenteritis kills pharmacies example protecting girls women cervical cancer madagascar half million children year worldwide introduced reimbursement programme turkey volibris used treat pulmonary addition synflorix rotarix november girls aged gsk committed supply cervical arterial hypertension enabled announced new commitment years living madagascar africa cancer vaccine cervarix gavi metastatic breast cancer patients india gavi alliance supply cervical cancer vaccinated human papillomavirus alliance reduced price initially access tyverb scheme offers vaccine cervarix part longterm hpv leading cause cervical cancer vaccine supplied gavi patients complete six months programme help protect girls women part demonstration project demonstration projects allowing treatment additional month free cervical cancer worlds supported ministry health unicef governments gain practical knowledge charge appropriate poorest countries see case study gavi alliance scalingup immunisation programmes middleincome countries benefit tiered nationally flexible pricing middleincome countries madagascar one seven subsaharan pricing vaccines also supply approach pricing middleincome countries collaborate gavi part gavi expects million vaccines pan american health countries based recognition longterm programme help protect girls girls worlds poorest countries organization purchases behalf economic social diversity disparity cervical cancer developing immunised hpv vaccines middleincome countries latin america exists within countries world cervical caribbean cancer deaths occurnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report access healthcare continued usa gsk offers several patient availability products joining forces increase impact new formulations better meet assistance programmes help eligible expanded global patient needs patients get prescription medicines commitment programmes combine strengths looking ways increase access treatments need programmes include pharmaceuticals consumer respiratory treatments developing countries continue build core range products formats healthcare businesses reducing pack sizes engineering commitment access cancer better meet needs people across globe collaborations better meet patient needs lowcost formulations reach greater specialty treatments including less able access afford products numbers patients example example businesses joined bridges access noncancer reengineered ventolin rotacaps using increasing access requires making forces tackle copd debilitating version established gsk inhaler medicines medicines affordable also incurable potentially fatal lung condition technology one five times less gsk vaccines access program available effective treatment affecting million people expensive produce new inhaler providing vaccines adult applicants patients need right medicines globally chiefly caused smoking available four markets philippines right place right time increase blamed copd deaths indonesia kenya nigeria gsk access senior disabled availability products many twofifths copd patients submitted regulatory approval patients enrolled medicare part expanding portfolios product continue smoke talking doctors markets ultimately hope open eligible patients enrolled registrations developing countries pharmacists treatment access many patients us patient assistance programs harnessing combined capabilities appropriate patients seretide advair currently unable afford inhaled respiratory provided prescribed gsk medicines consumer healthcare pharmaceutical respiratory medicine also medicines divisions increasing local manufacturing niquitin smoking cessation vaccines worth total us capacity building markets serve products help affected risk new formulations potential million million million quit tobacco working revolutionise paediatric healthcare million portfolio expansion product registration pharmacies promote awareness example working biological e remain committed improving committed expanding portfolios earlier diagnosis underrecognised leading indian vaccines company productivity rd develop increasing availability medicines condition programme live brazil firstofitskind combination paediatric innovative new medicines greater noncommunicable diseases argentina australia turkey russia vaccine protect children polio efficiency improved efficiencies cancer diabetes well infectious expanded infectious diseases new fully seeing within rd business diseases developing countries see liquid formulation enable fewer organisation also enabling us part effort working another collaboration working injections children improve flexible pricing medicines regulators increase registration pharmacies enhance help compliance immunisation schedules medicines existing portfolio patients consumers get treatments advice need people catch programme developing regions like africa pharmacies aims bring established products chief source healthcare africa developing countries received approvals programme start nigeria kenya products treating non angola cte divoire communicable diseases respiratory countries follow increasing antibiotics oncology also contacts pharmacies boost offering affordable pricing options new availability healthcare expert advice drugs first enter market need themnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report access healthcare continued local manufacturing capability building strengthening healthcare systems africa save children west also help strengthen healthcare gsk manufacturing sites outside central africa care international systems initiatives tackle europe north america operating commitment asia invested million counterfeit medicines see behaviour local manufacturing sites develop based profits total skills technical expertise continue work partners support million since train build development strengthening healthcare workforce countries cut capacity among health workers infrastructure anticipate could improve access costs production transportation healthcare million underserved people preparing pandemic projects include training vs transferring technology produce drugs community health workers angola care signed agreement vaccines one sustainable gsk committed strengthening nearly mothers young world health organization donate ways bridge access gap healthcare infrastructure developing children suffering malaria respiratory real time pandemic influenza developed developing world countries working partners explore diarrhoeal diseases equipping vaccine production two million number joint ventures technology new healthcare delivery models community health volunteers skills treatment courses antiviral medicine transfer arrangements help build supporting projects worlds needed screen children distribution countries need capabilities developing countries least developed countries ldcs malnutrition liberia reaching event future pandemic research manufacture vaccines hope improve access healthcare one million people increasing access markets million underserved people expectant mothers nepal training agreement known standard example joint venture biological e health workers providing operational material transfer agreement confirms continued work towards goal india working early stage support equipment details event pandemic vaccines training community health research development new projects found website available soon workers scaling activities paediatric vaccine see also first production cycle completed nonprofit partners collaborating possible conduct indepth longstanding technology transfer addition donation gsk also companies sectors create innovative monitoring track progress manufacturing agreements oswaldo reserve volumes pandemic models strengthen healthcare systems also committed us cruz foundation brazil areas essential vaccine real time production one million community health workers brazils universal immunisation reinvesting community antiviral medicine eight million campaign led united nations programme announced plans since reinvested treatment courses sustainable development solutions develop new million manufacturing profits generate ldcs community required network fund new online facility india invested programmes strengthen healthcare operations room monitor progress million building manufacturing systems improve access healthcare campaigns efforts train growing network last decade countries numbers health workers subsaharan training frontline community health workers africa overall goal ensure one reach millions people remote million health workers operating rural rural areas vaccines medicines areas help meet health advice central programme related millennium development goals working amref east southernnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report access healthcare continued partnering explore new healthcare continue work one family health delivery models enterprise uses franchise system lack finance poor access nurses operate local clinics essential medicines identified extend access basic healthcare kenya world health organization major rwanda committed barriers strengthening healthcare million three years help open systems africa september nurseowned child family wellness announced new partnership barclays health posts rwanda support increase access affordable healthcare rwandan government medicines zambia supporting small business development job creation together invest million three years project explore build cost effective private sector medicine supply chain establish small enterprise health outlets test affordable micro health insurance product embed healthcare education existing community finance networks aim reach one million zambians improving healthcare delivering safe water senegal create model scaled replicated across africa reinvestment maternal neonatal deaths partnership vodafone programme helping improve postabortion care educating harnessing power mobile technology access healthcare services young community health workers home births help increase vaccination rates children mothers senegal raise awareness important children africa common infectious many children five die health issues among community diseases mobile phones used create preventable diseases diarrhoea addition project also trained vaccine records send text message malaria pneumonia health workers community leaders reminders mothers share stock data building existing gsk health communityled sanitation taught real time ensure vaccines available sanitation project partner bricklayers build ventilated latrines needed save children trained cleaned local water sources set initial oneyear pilot project nurses improving knowledge ensure safe water supply clinics mozambique immunisation conducting audits peoplenote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report access healthcare continued focus noncommunicable diseases comes public health issues access affordability developing world focus developing countries market predominantly infectious diseases access unit responsible increasing malaria yet chronic noncommunicable patient access medicines diseases ncds diabetes vaccines developing countries see cancer cardiovascular chronic also focus educating respiratory diseases account nearly healthcare providers recognise half deaths disabilities countries symptoms treatment options lowest incomes analysis revealed high levels growing fast treatment diagnosis asthma five urban centres bangladesh lack focus ncds developing cambodia kenya senegal zambia countries compounded rolled respiratory masterclass misperception diseases like cancer awareness education sessions key developed world disease regions educating healthcare changing lifestyles demographics professionals asthma diagnosis mean global burden ncds treatment options similarly fact developing world supporting several training programmes ncdrelated deaths occur lowand health care providers africa ranging middleincome countries tackling basic oncology training general significant challenge important focus doctors formal pathology training gsk adopted partnership december announced specialist doctors strategic approach ncds partner several organisations formation oncology clinical particular emphasis developing prevention health education focus combating ncds translational consortium collaborative countries includes four main risk factors contribute developing world example scientific research network comprised onset ncds smoking working amgen biopharmaceutical six internationally renowned innovation research alcohol poor diet lack exercise company use expertise several comprehensive cancer centres north assets clinical development consumer business several asian countries support launch america europe consortium four priority ncds initiatives address risk factors vectibix patients metastatic foster scientific collaboration among working adapt existing products focusing particular smoking colorectal cancer bangladesh members gsk preclinical better meet needs patients cessation better oral health improved support ngo seeking establish translational clinical development emerging markets example nutrition example patients breast cancer screening programmes novel anticancer therapeutics conducting research improving flolan copd working tackle use mobile phones increase treatment advanced stages conditions chief cause smoking see adherence treatment programmes pulmonary arterial hypertension allow source httpwwwhsphharvardedunewshsphin women breast cancer thenewsglobalhealthnoncommunicablediseases greater stability higher temperatures bloomnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report diseases neglected tropical diseases polio malaria affect billions people worlds vulnerable communities aim help treat prevent developing world ultimately eliminate diseases tackling diseases developing world neglected tropical diseases progress date researching new treatments improves health boosts progress commitments made existing treatments visceral economic development work commitment london declaration tracked leishmaniasis ntd fatal left partners public private sectors annual public scorecard untreated costly research new vaccines engage help eliminate control ten neglected tropical first two years partnership challenging investing diseases affect billion people communities adopting preventive endemic countries developed multi development better affordable including elimination lymphatic filariasis measures make medicines continued investment rd ongoing year plans fight ntds gsk treatment specialist rd unit tres treatments available affordable product donations contribution london pharmaceutical partners meeting cantos see screening achieved major milestone declaration neglected tropical diseases increased requests drugs compound library molecules development worlds first inhibit growth leishmania parasite neglected tropical diseases ntds present gsk donated billion malaria vaccine intend file working university significant health risks worlds albendazole tablets support efforts approval dundee project identify class poorest communities one billion eliminate lf countries deworm chemicals combat parasite also advocate adoption public people including million children schoolage children countries policies provide adequate financing affected ntds symptoms often albendazole donation programme also researching new treatments mechanisms gavi alliance prevent people working children reached million people african trypanosomiasis sleeping sickness funding immunisation poor countries going school making harder million children since administered orally global fund fight aids tb escape poverty began donated eliminating need injections malaria board roll million albendazole tablets lf trained healthcare workers aims leading partner london declaration back malaria partnership elimination million tablets treat increase availability treatment gsk working bill melinda founding member global alliance soiltransmitted helminths donations communities reduce strain medical gates foundation eliminate lf support whos goals eliminate services open lab pharmaceutical companies donors lf globally deworm school age collaboration northeastern university national governments help control children countries intestinal worms spanish research council eliminate ntds affect endemic promising chemical hits identified billion people investigated significant contribution collective also working logistics partners commitment elimination improve supply delivery ntd open lab collaborations new york lymphatic filariasis lf control donations manufactures recipient university university georgia also soiltransmitted helminths intestinal worms countries donors endemic country aim develop effective treatments donation albendazole tablets leaders committed us million american trypanosomiasis chagas well collaborating public needed disease using gsks compound library private partners research new treatments working partners close funding gaps ntds supporting development new medicines diagnostic tools find investigate treat prevent diseasesnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report diseases developing world continued polio immunisation programmes using oral malaria health impact rtss vaccine polio vaccine opv relatively evaluated context existing malaria commitment inexpensive taken orally commitment control measures insecticide vaccine distributed volunteers treated bed nets research centres continue support objective eradicating without need trained healthcare build year commitment contribute seven african countries latest trial polio providing vaccines unicef fight malaria continued rd investment worker injection equipment results demonstrated vaccine achieved partnerships ground provided million doses global continued protect young children polio eradicated many polio eradication initiative gpei public malaria one worlds deadliest infants clinical malaria months countries still endemic private partnership led national diseases affects many worlds vaccination afghanistan nigeria pakistan governments poorest people estimated billion based findings plan submit recent outbreaks syria people half worlds population since contributed regulatory application european committed supporting risk contracting disease billion doses committed medicines agency ema objective eradicate polio completely approximately malariarelated deaths meeting least gpeis approved believes policy providing vaccines unicef reported year mainly children current polio vaccine requirements recommendation vaccine candidate achieved objective five living subsaharan africa malaria procured unicef could possible partner achieved estimates could related illnesses mortality cost africas systematically stockpiling opv meet multiple stakeholders including african see new cases year economy nearly billion year demand expected require governments ensure delivery worldwide within decade around billion doses gsk committed tackling malaria implementation vaccine across africa gsk played leading role efforts researching vaccine developing new takes place rapidly possible countries polio eradicate polio last years treatments promoting use existing eradicated opv phased groundbreaking achievement builds continue collaborate innovate preventive measures increasing access replaced inactivated polio vaccine year commitment combat achieve goal prevent disease antimalarials least developed countries ipv prevent low risk polio malaria continued rd investment resurfacing countries already declared reemerging live vaccine achieving milestone vaccine partnerships ground polio free already produce supply ipv variety achieved major milestone invested million development global healthcare company role developed countries development worlds first rtss publicprivate partnership includes manufacturing vaccines using investing developing lower cost malaria vaccine rtss clinically path malaria vaccine initiative research expertise explore new ways combination vaccines containing advanced malaria vaccine candidate date mvi support bill melinda tackling polio also price vaccines vaccines polio diseases almost halved number malaria cases gates foundation help make sure need access single vaccine developing world young children aged months first price rtss cover cost investing nextgeneration see vaccination reduced around manufacturing vaccine together products part longterm quarter malaria cases infants aged small return around commitment fighting polio preventing weeks first vaccination shown reinvested rd secondgeneration resurgence invested building results largescale phase iii trial malaria vaccines vaccines manufacturing facilities ensure long published october tropical diseases term supply vaccines example investing million building new facility wavre belgium begin production note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report diseases developing world continued developing new treatments resistance current malaria treatments read online increase supporting publish detail online key development new medicines issues including research facility tres cantos see developing medicine tafenoquine clinical trials developing world partnership medicines malaria developing world vaccine production venture mmv treatment technology transfer relapse prevention vivax malaria strain affects millions people asia ip access medicines south america based clinical trial developing countries results progress pandemic preparedness development investigational medicine developing countries hope could offer convenient single dose alternative current day technology transfer capacity building standard treatment us food developing countries drug administration granted working together health mothers tafenoquine breakthrough therapy children designation partnering tony blair faith foundation sierra leone gsk briefing noncommunicable promoting preventive measures diseases developing world gsk works improve prevention treatment malaria subsaharan africa part commitment expanding contacted since september gsk position statement post africa malaria partnership healthcare access rural communities confirming acting advice development agenda partnering tony blair faith provided supports local ngo programmes pricing reimbursement foundation tbff sierra leone committed million investing community initiatives since reach million people nearly product donations programme gsks support population vital malaria partnered organisations ground tbff continue scale work prevention education promote use existing interventions sierra leone reach bed nets indoor residual pioneering healthcare model households plan explore similar spraying projects focus tbff trained local opportunities countries community health worker training religious leaders turn educated high malaria burden community empowerment well malaria faith champions frontline model could effective reaching pregnant women children messengers engage specific five years ghana working families programme already human development organisation fhi reached around one million people nigeria carter center nearly households kenya save children tanzania amrefnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report hivaids viiv healthcare global specialist hiv company established gsk pfizer joined shionogi dedicated tackling hiv researching new treatments improving access medicines working communities combat stigma discrimination million people live hiv viiv progress pipeline viiv healthcare also supports collaborative improving access hiv treatment healthcare researching new treatments currently four clinical phase research trials resourcepoor settings improving access medicines working assets viiv healthcare portfolio understand public health issues commitment communities combat stigma several preclinical discovery programmes prevention mothertochild hiv viiv healthcare continue increase access discrimination partnership range partners transmission hivtb coinfection medicines care adults children living including gsks hiv discovery total end clinical hiv around world help world health researching new treatments performance unit pharmabiotech trials underway trials organization unaids achieve goal viiv healthcare focused driving academic institutions engaged field paediatric studies african countries reaching million people globally antiretroviral innovation hiv research discovery treatment treating hiv examples participating paediatric studies companys goal find new ways partnerships efforts understand new include malawi south africa tanzania million hivpositive people limit impact virus developing new modes action antibody therapy new uganda zambia zimbabwe low middleincome countries lack medicines effective ways delivering existing therapies access antiretroviral arv therapy viiv improve tolerance treatment adherence addressing gaps paediatric hiv nanotechnology long acting delivery healthcare aims play part meet existing options treatment care prevention hiv understanding challenge improving access medicines even new hiv infections among children launching tivicay dolutegravir pathway functional cure disease need treatment continue decline globally estimated work experimental integrase inhibitor viiv healthcare reached gsk continues progress gsk million children age viiv healthcares access policy applies important milestone approval tivicay first new treatment investigational integrase inhibitor still living hiv approximately middle income countries low income class antiretroviral drugs children live africa one countries least developed countries delivered august us fda approved tivicay dolutegravir recently approved tivicay dolutegravir barriers preventing scaleup treatment subsaharan african countries nearly distinct new chemical entity lack affordable medicines hivpositive people live low investigational integrase inhibitor two integrase inhibitors similar acceptable use children viiv income least developed subsaharan blocks hiv enzyme integrase structures antiviral activities differ healthcare therefore prioritising research african countries viiv healthcare prevents hiv replicating adults respect certain attributes improve diagnosis treatment offers royaltyfree voluntary licences children years older living hiv gsk particular longer care infants children living hiv notforprofit pricing viiv healthcare followed approvals elimination half life slower absorption addition viiv healthcares ongoing royaltyfree voluntary licence agreements markets including argentina canada injection potentially permitting use work develop new formulations generic manufacturing companies chile approval europe january dolutegravir brings new treatment longacting injectable formulation current portfolio children viiv located several countries enables second study longacting injectable healthcare supporting collaborative produce sell lowcost versions options patients october viiv form drug set begin research trials investigating prevention gsks entire arv portfolio public healthcare also submitted regulatory second quarter mothertochild hiv transmission sector donor agency programmes applications canada eu paediatric treatment strategies addition voluntary licence agreement usa single tablet regimen viiv healthcare supports diverse research manufacture tivicay dolutegravir low combining dolutegravir abacavir initiatives million paediatric income countries least developed lamivudine known dolutegravirtrii innovation seed fund countries subsaharan africa reduce number pills required signed late people living hiv source httpwwwunaidsorgenresourcescampaigns globalreportfactsheetnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report hivaids continued middle income countries viiv healthcare supporting communities affected hiv positive action southern initiative reaches vulnerable communities living hiv adopts flexible pricing policy varies zero new infections zero aidsrelated us according gdp burden deaths zero discrimination three hiv epidemic individual countries primary goals unaids getting zero another key approach creating campaign involves multidimensional southwest louisiana aids council eighteen months enrolment average partnerships manufacture medicines strategy address hivaids one original grantees positive cd counts indicate strength locally brings cost pandemic viiv healthcare contributing action southern initiative provides immune system increased builds skills local economy goals support support educational services newly average levels hiv blood example strategy action partnership communitybased diagnosed care people living participants decreased commercialisation maraviroc india organisations strengthen education hiv rural lake charles louisiana encouraged findings partner emcure launched build support services local healthcare addition councils initiatives improve show model linking december capacity reduce stigma treatment adherence services engaging retaining underserved discrimination towards people living region resulting better health outcomes usa nearly million people populations hiv stable medical hivaids live hiv infection viiv healthcare twoyear period individuals care working said angela hursey helps uninsured people access making impact prevention enrolled councils initiatives council seeing medicines patient assistance mothertochild transmission hiv linked care treatment improved linkage retention rates program addition patient savings part commitment help children number people undetectable seeing measurable evidence card program helps eligible patients living hiv positive action level hiv blood rose linkage care treatment adherence save outofpocket costs viiv children fund pacf supports reducing risk illness leads better health outcomes including healthcare medication organisations across countries deliver living hiv risk higher rates undetectable viral loads prescribed tivicay dolutegravir prevention mothertochild transmission transmission partner among people hiv total potential amount savings hiv since march pacf increased per month committed million services reaching women improving access medicine children children families affected hiv powerful example one million grants hivaids patent pool programme focused creating smaller pacf grants makes awarded support organisations february viiv healthcare extended opportunities support capacity building real difference group life viiv healthcares global positive action commitment supporting children living among groups receive apply concern malawi identified programme supported hiv agreement grants example set significant issue men often get communities vulnerable hiv medicines patent pool mpp unitaid pacf online wwwpacfonlinecom involved provide support encourage diseases years positive action backed public health mechanism online community includes regular uptake prevention mother child focuses funding capacity building significant development granted mpp training webinars groups share transmission services group tripled organisations help improve access voluntary licence paediatric formulations experiences learn number men attending clinic visits care key populations countries antiretroviral medicine abacavir partners reached individuals facing threats countries hiv positive people half men half women stigma discrimination children live community awareness campaigns source httpwwwcdcgovhivstatisticsbasics ataglancehtmlnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report health wellbeing committed improving health wellbeing communities worldwide funding supporting local programmes make communities real difference gsk supports development healthcare continue work phase total giving type infrastructure contributes scientific personal hygiene sanitation education education well assisting humanitarian programme brazil work roma relief efforts maximise impact communities eastern europe improve support select programmes health education number initiatives designed sustainable long term aimed improving maternal child partner local global organisations health partnership save encourage employees participate children volunteering pulse orange patient assistance programs day programmes see pages help underprivileged families usa product financial donations access essential healthcare accounted cash health economic empowerment product inkind global community investment total giving see time women latin america totalled million million compared line commitment management million million reinvest profits generate threeyear partnership womens least developed countries invested donated medicines valued programmes supported financial giving development organisation pro mujer million million since aims empower women million cost including million training frontline community health latin america lift albendazole tablets fight lymphatic workers rural areas see poverty give families access filariasis soiltransmitted helminths see gsk values product donations cost goods basic healthcare often first time believe truer reflection cost gsk wholesale acquisition cost value cost reported giving women access financial p dero livd eu rc et oa uti ro pn r tw err sth e r ic ai rll eio sn dw ire er ce ino w uh sto rl ye foa rl e vr l u iw nh gi c ph ro ds uu cs te dd ns ts oa nn sd tr hd e n th ae l vp ah lua erm services education small repayment production donations based wholesale loans start businesses pro relief ima world health map international acquisition cost million mujer helps improve livelihoods project hope humanitarian aid contributing fund pay partners distributed donated medicines health wellbeing health screenings medical services countries including supplies education families health screenings antibiotics basic medicines pro mujers team trained healthcare affected conflicts natural disasters professionals encourage positive health example earthquake pakistan giving million behaviours support early detection oklahoma tornado wildfires prevention chronic diseases usa gsk also responded typhoon philippines providing million cash since began programme us million donated medicines already reached cash donation us product inkind women touched lives well local staff volunteering support time million families argentina affected communities management bolivia mexico nicaragua peru total note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report health wellbeing communities continued gsk impact awards live loving life arts therapy name uk usa psychosocial support cancer patients lithuania gsks annual impact awards channelled million loving life innovative threeyear past years charities programme across five cities lithuania improving health uk extending access healthcare beyond usa traditional medicine include psychological support arts therapy working increase impact cancer patients families awards example gsk increasing quality life impact awards network training programme uk offers leadership lithuania healthcare system development essential skilllearning focused exclusively traditional opportunities networks national medicine emotional support summit brought together past newly diagnosed cancer patients winners share impact limited following gsk survey able make cash highlighted social integration prize gsk psychological support unmet needs nurturing talent south asia cancer patients developed usa expanded scope programme collaboration gsk impact awards recognise centre oncopsychology th year horlicks wizkids students also recognised nonprofits address pressing communications local ngo programme become south asias involvement community projects community factors safety largest interschool competition ranged tutoring children access healthy foods recreational gsk provides funding practical literary art creative cultural events underprivileged fishing community spaces support families support implementation students ages years raising profile orphanage social networks contribute expansion programme winners announced fiveday health wellness also established supported patients living reaching six million event includes physical training gsk impact grants new programme cancer stimulate development students across cities bangladesh personal development overall grooming support collective impact type support lithuania india nepal pakistan sri lanka uae communication workshops community several nonprofit partners working centre developing new course programme encourages individual service team building activities together improve health psychosocial oncology partnership team performance across streams like leadership skill development four disadvantaged young people metro university health sciences literature theatre music quizzing oratory winners horlicks wizteam denver colorado greater st louis lithuania gsk supporting skills culinary skills creative writing iq year given opportunity missouri communities international conference ngos tests art design subjects participate international student working area planned traditionally receive much focus exchange programme schools regionnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report behaviour focus gsk things important valuesbased andrew senior scientist culture designed ensure put patients worked gsk seven years works biopharm research customers first development stevenage site uk like employees andrew uses values code conduct guide decision making knows encourage employees speak concerns read section behaviour overview putting patients first sales marketing values principles research practices working healthcare professionals sales marketing manufacturing supply public policy patient advocacy approach tax note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report behaviour overview efforts meet global healthcare glance values principles external perspective challenges ensuring sustainability business navigate wide range systematically assessed gsks human rights impacts developed plans relating gsk first pharmaceutical complex ethical issues associated every stage development delivery values principles supply chain embedding global company join alltrials standards country level products research employees must uphold code campaign february saying manufacturing supply sales conduct addition designated see company owes marketing managers completed annual ethical thousands people taken leadership certification certify four core values transparency awareness understanding compliance research practices part clinical trials make respect people integrity patient gsks values policies facilitate research progress data generated available focus guide us everything medical science patient care people partners launched online request system scrutiny many organisations suppliers expected adhere external researchers access detailed representing patients doctors strict codes ethical conduct anonymised patientlevel data clinical regulators applauded gsks trials also became first company support values see publish clinical study reports formal reports decision looking gsk last six years evolved design methods results trials develop strong leadership business model better meet societys expectations leading internal perspective see clinical trial reporting industry many areas increasing urgently needed across industry transparency clinical research ur commitment transparency working healthcare professionals transforming way incentivise enables broader scientific began process end direct payments sle lane alltrials campaign sales teams engage community examine data healthcare professionals speaking healthcare professions engagements attendance medical closely conduct research conferences manufacturing supply chain recent allegations fraudulent behaviour help advance medical began rolling anticounterfeiting china underlined importance science improve patient care see programme provide unique efforts prepared take serial numbers packaging lines also responsibility decisive action change way across manufacturing sites operate failing meet ensure vital contribution sales marketing next four years expectations stakeholders made people participate extended patient first programme us business base sales team incentives trials used help scientific knowledge behaviours scientific understanding support ethical patientfocused business practices instead sales volumes james shannon chief medical officer gsk see see note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report putting patients first sales marketing constantly challenge patients come first work hcps number doctor nurse new compensation scheme ways including research prescriber better meet expectations reward sales conduct perception conflict society marketing professionals behalf soliciting interest remain reinforced commitment well use expertise gsk products committed continue putting patients first technical knowledge therapy areas support hcps announcing fundamental improve patient care changes help us began two changes sales gsks overall business transparency year process end marketing practices performance built see practice paying hcps way interact experience usa speak behalf healthcare professionals shown products disease approach pays instead individual sales areas audiences improved customer targets prescribe influence satisfaction see incentivise sales prescribing move marketing teams detail also changing designed provide patients products prescribers relationship healthcare greater confidence ensure interests professionals hcps whenever talk anote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report values matter operate world interactions patients prescribers payers governments must always live values principles making sure people behave ethically aligned performance reward context concerned critical reputation values systems values introduced new disappointed allegations fraudulent responsible business impact performance system formally behaviour china business put values heart every commercial success evaluates employees need taking matter extremely seriously decision make values also senior cooperating fully chinese authorities plus employees around operate transparency people disincentivise unethical working world use code conduct unified taken number actions practices using clawback mechanism guide gsk spirit company demonstrate respect people including also commissioning allows us recover performance related pay culture inspires sense individual independent report international legal act integrity see people responsibility collective purpose firm ropes gray extensive code revised simplified remain patientfocused annual business ethics certification experience anticorruption language increased emphasis programme ethical leadership certification international risk values speak programme requires designated managers certify living values gsk committed learning lessons understanding compliance gsks code translated focused integrating required result chinese values policies responsibilities languages provides practical working valuesbased culture across company investigation take steps lead support ethical work environment guide employees apply gsk clarified expectations employees necessary outcome remain fully failure complete certification values behaviours supported leaders simplified detailed committed china supporting specified deadline triggers disciplinary online values resource centre policies underpin code conduct governments healthcare reforms followup human resources provides tools information aid promoted speak whistleblowing supplying products patients decisionmaking mechanism encourage employees bribery corruption report violations gsks zero tolerance approach bribery require suppliers business corruption detailed preventing partners comply high standards reviewed enhanced corrupt practices policy applies expectations ethical conduct corporate policies ensure policies everyone gsk well third parties set third party code support code conduct act behalf company conduct employees third parties written way employees find clear antibribery corruption programme report concerns violations concise accessible aim includes online facetoface training codes anonymously robust improve understanding therefore targeted employees working highrisk speak programme enable greater compliance roles conduct regular audits support bribery corruption programme performance reviewed monthly oversight committee suspected breaches anticorruption policies reported anonymously without fear retaliation whistleblowing channels see note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report values principles continued medical governance employee compliance scientific gsk takes action following misrepresentation medical governance framework ensures engagement policy monitored part data published research paper always apply good medical science global risk management compliance integrity ethics discovery framework well gsks development marketing gsk corporate integrity agreement usa became aware allegations committed highest ethical products overall responsibility medical conducted reviews misrepresentation data research scientific standards regulators governance sits chief medical including nine focused paper written shanghaibased gsk physicians patients officer senior physician publication process engage scientists published nature medicine confidence research carry gsk supported medical healthcare practitioners enhance published study following investigation gsk took governance executive committee processes procedures ensure laboratory research involve appropriate action five rd employees require external partners adhere interactions physicians giving investigational drug among named authors similar medical governance appropriate transparent individuals publication left company also standards gsk established broader scientific data review based principles scientific integrity research critical team overseen independent chair scientific engagement engagement gsk encouraging work june concluded outside gsk scientific engagement policy provides shift emphasis branded investigation published study set global principles standards commercial spaces scientific regretfully established certain data team found evidence patient guide us distinguishing nonpromotional booths medical conferences misrepresented shared conclusion safety compromised reason scientific dialogue external stakeholders european respiratory society ers nature medicine recommended stop suspend clinical research promotional activity support conference retraction paper retracted teams recommendations fully approved products example nature medicine precautionary implemented embedded exception public health campaigns scientific engagement area event measure early clinical study standard practice conducted partnership global public used interactive media demonstrate healthy volunteers receiving organisations wait product heritage leadership commitment investigational drug targeting crucial role interleukin helper type granted marketing authorisation regional tackle respiratory diseases staffed signalling pathway also stopped survival expansion autoimmune disease senior gsk medical staff including published nature medicine national regulatory agencies heads medicine several countries sponsoring supporting related scientific teams across nonproduct general disease area business first trialled approach education activities ers conference standards adopted pleased note others followed voluntarily set us apart peers chosen go beyond required codes practice legislation demonstrate commitment integrity transparencynote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report values principles continued compliance addressing misconduct majority employee types policy violation global ethics compliance team committed transparency discipline due continued provides tools oversight guidance report annually addressed focus attendance payroll category improve compliance external misconduct within business violations regulations internal policies team contacts attendance issues mainly works partnership business made ethics reported manufacturing business promote decisionmaking based compliance channels mixture implemented tighter controls values compliance allegations misconduct requests ensure maintain build information guidance strong track record compliance march refreshed employee policy violations thought campaign raise awareness gsks reported whistleblowing whistleblowing programme encourages attendance payroll instances employee programme raises awareness good manufacturing distribution practice enables employees third parties encourages employees report unethical code conduct discipline policy violations report unethical illegal conduct illegal conduct falsification documents gsks code conduct gsk marketing promotional activities policies external legal standards employees dismissed employees remain company lora cv ae l l w od rk e rx ep ge un ls ae tions concerns raised multiple following policy violation receive retraining agreed leave company voluntarily communication channels including increased monitoring support telephone hotlines online form cases retraining extended available languages line managers disciplinary actions included employees colleagues prevent representatives global ethics documented warnings making similar mistakes compliance group human resources policy violations related breaches external codes legal also available listen violations sales marketing gsk found breach external address concerns provide local policies resulted industry government promotional codes communicators toolkit materials dismissals separations times compared available languages encourage documented warnings investigate every breach people report concerns external code take steps prevent reoccurrence may include retraining corrective action including disciplinary actionnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report values principles continued human rights result focusing better privacy data security understanding human rights risks gsks global organisation gsk collects commitment supply chain address uses maintains vast amount well embedding global personal information employees address un guiding principles business standards diversity equality people participate research human rights across operations supplier relationships inclusion country level also healthcare professionals updated human rights statement based partner committed protecting gsk signatory un global findings assessment data require employees compact voluntary global standard suppliers comply global privacy human rights labour environment activities embargoed countries principles ensure personal anticorruption support un guiding stakeholders concerns data collected used processed principles business human rights businesses operate countries transferred stored appropriately committed upholding un targeted sanctions laws cuba securely line legal requirements universal declaration human rights north korea iran sudan syria oecd guidelines multinational share uns belief people june uk information enterprises core labour standards set denied access medicines commissioners office approved gsks international labour organization regime operating binding corporate rules bcrs set country aim supply medicines legally binding global policies based part support un vaccines countries need european union laws ensure guiding principles worked bsr wish purchase including essential compliance crossborder transfer nonprofit external consultancy medicines sanctioned countries requirements research employee expertise business human rights compliance applicable sanctions personal information bcrs make undertake systematic assessment export controls also comply possible transfer personal data identify gsks human rights impacts based disclosure requirements iran threat internationally gsk entities without assessment prioritised seven reduction syria human rights act individual privacy agreements every areas examine gsks policies european union country however data process potential positively transfers bcrs also need negatively impact human rights authorised european country access healthcare global warming impact gsk continue progressing propellants used inhalers clinical bcr national authorisations trial standards employment practices country patient safety product counterfeiting use third party suppliers increase focus information security gsk established office chief information security officer provide strategy direction oversight building gsks global information security capabilitiesnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report research ensure research practices meet highest ethical standards make patient safety priority stages wherever operate practices clinical research audits contract research research essential create next organisations carry clinical generation medicines combat unmet trials behalf medical needs improve existing treatments audits gsk local operating conduct clinical trials patients companies involved clinical healthy volunteers evaluate safety trial activities efficacy new medicines develop innovative applications known treatments reviews new drug application nda annual reports conduct trials accordance international conference addition conducted investigations harmonisations good clinical practice suspected irregularities took corrective guidelines trial protocols reviewed action appropriate independent independent ethics committee regulatory authorities also performed made members public medical providing access trial data benefit medical science patient care inspections gsk sites investigators professionals scientists used conduct clinical trials power reject stop clinical trial gsk became first company researchers requesting access transparency clinical research launch online system enabling data must show use employees must complete training good external researchers request access research commit publishing clinical practice gcp undertaking commitment detailed data sit behind findings independent panel roles related gsksponsored clinical clinical trial results experts reviewing proposals ensure research employees completed transparent possible clinical trial proposed research appropriate data including publishing clinical study reports without gcprelated courses either online described sea change clinical patientlevel data outcome trials medicines person confirm conduct conducted gsk within appropriate process science commitment enables gsk system launched first trials line standards making available researchers access anonymised researchers examine data closely step working others conduct audits trial sites patient level data scientific enquiry conduct research help industry public charitable contract organisations carry trials advance medical science improve patient sector encourage development sharing results research vital behalf care external researchers submit broader independent system gsk helps ensure important research proposals request access data studies conducted multiple conducted clinical quality contribution made people participating anonymised patient level data studies organisations made available assurance assessments confirm trials used maximum effect furthering started medicine research january took conduct trials reflects scientific knowledge understanding approved regulators terminated important step path transferred standards including built longstanding development regularly update new multisponsor request site commitment clinical trial transparency audits investigator sites first company introduce new list include global studies since clinicalstudydatarequestcom conducting gsksponsored trials system enables researchers access end approximately includes studies multiple organisations studies made available audits gsk processes researchers also able ask new drug application reports submitted us availability data studies food drug administration provide update nature online news article status study completed progressnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report research practices continued detailed anonymised patientlevel data fundamental ethical principles gsks global safety board chaired animal research trials see case study expanding regardless take place chief medical officer composed information made publicly available senior physicians scientists commitment conduct clinical trials countries clinical study register makes decisions product safety issues medicines likely suitable rigorously challenge need animal studies remit ensure safety key register receives average wider community gsk work minimise impact animal welfare focus research teams review investing development alternative studies visits month conduct clinical trials investigational benefitrisk evaluations gsk products sharing animalbased data includes summaries trial medicines country known development market results posted regardless outset intent pursue recognise animal research also internal risk advisory whether outcomes might considered registration make medicine available subject ethical concern use panel encourage sharing information positive negative use country alternatives animals whenever best practices within company expanded include clinical study aim carry studies patient safety reports csrs formal study reports pharmacovigilance fewest animals possible however animal design methods results clinical pharmacovigilance relates detection studies remain vital part research trials form basis submissions commitment monitoring assessment understanding many cases way regulatory agencies prevention adverse effects demonstrate effects potential new continue ensure interests safety patients consumers paramount importance way drug related problems gsk collaborates medicine living body tested gsk first company publish design undertake clinical trials product industry peers regulators healthcare humans regulations require us test csrs available personal quality assurance monitoring reporting providers patients interested safety new medicines animals information removed trial adverse events ongoing product usage parties continually enhance science evaluated clinical trials published medicines patient safety fundamental priority pharmacovigilance improve approved terminated development need use animals gsk medicines potential risks communication medicines committed publishing csrs research committed acting well benefits critical part efforts improve current trials approved ethically providing health identify evaluate minimise safety pharmocovigilance process research medicines dating back formation wellbeing office animal welfare concerns ensure overall benefits teams perform benefitrisk evaluations gsk starting ethics strategy led chief medicine outweigh risks life cycle medicines commonly prescribed medicines also veterinary medicine develops policies results presented global support alltrials campaign calls robust policies governance oversees humane responsible use safety board created new full reporting methods results framework help us detect act animals across gsk created team enhance pharmacovigilance trials side effects may associated new system establish global quality operating model medicines also apply computerised standards training facilitate clinical trials developing countries statistical tools analyse safety information defined world health organization sharing best practices improving clinical trials take place example identifying unexpected animal welfare developing countries legitimate concerns adverse events side effects reported raised running trials disproportionate basis countries health services may committed continually evaluate well developed gsksponsored communicate transparently patients clinical trials conducted according prescribers payers regulators benefits risks medicinesnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report research practices continued studies conducted external contractors reducing number animals used performance animals research including behalf subject high research reduced number animals used research carried contractors standards carried within number animals genetic toxicology research declined lower mice nonrodents account less gsk facilities past five years testing pharmaceutical ingredients despite two main drivers number animals used animal quality assurance group supporting redevelopment animal use rd investment vaccine less animals use assessed care welfare programmes international guidelines enable sales increasing period nonhuman primates contractor supplier us integrate testing rodent percentage change animal use organisations vast majority met studies already conducted compared key drivers animal use standards animal welfare implemented aspects safety type recommendations improvement integrated study helps reduce animal cases contractors fail adopt use improve scientific data recommendations show commitment refining techniques minimise pain continuous improvement following site distress improve welfare visit stop working animals every species certain defining rs behaviours understanding encouraging approach animal research based behavioural standards helps us rs promote welfare species research studies replacing animal research established set behaviour standards animal used within gsk facilities methods possible scientists mice including nest building animals used contractors behalf gsk safety pharmacology group rd investment plus vaccine sales exploration exercise opportunity example developed test uses interact hide others figures normalised first year data formation heart tissue developed adult human opportunity gnaw glaxosmithkline data includes animal research conducted external stem cells ipsc measure effect contractors behalf data unavailable working species compounds electrical activity species used gsk animal research heart test allows us identify publish results scientific journals discard compounds potential engage scientists induce fatal arrhythmias patients early regulatory authorities influence broader development replaces animals industry standards share best practices tests traditionally used identify learn others liability sponsored experimental design workshops gsk animal researchers uk usa considered could reduce number animals used research changing way design mouse experiments rat guinea pig rabbit othernote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report working healthcare new measures announced transform way work healthcare professionals professionals transparency commitment gsk committed publishing payments make hcps hcos already continue drive valuesbased approach sales several countries including australia marketing practices across world interests consumers patients core france netherlands portugal slovakia japan uk usa line locally payments hcps agreed government industry association end announced standards gsk continue disclose twoyear process change payments make clinical research work hcps becoming first advisory activities market research sector move towards ending practice countries continue support paying doctors speak behalf work towards transparency providing direct financial support countries industry associations individuals attend medical conferences governments establish specific guidelines disclosure example efpia starting phase code payments practice paying hcps speak behalf products disease areas also continue work towards audiences prescribe influence publishing global figures aggregate prescribing work implement level payments hcps changes effectively line local continue advisory activities laws regulations across global clinical research business start still important role play continue offer appropriate fees changes designed modernise supporting education hcps hcps providing services gsk relationship healthcare professionals providing accurate information sponsored clinical research advisory bring greater clarity confidence medicines help make best activities market research whenever talk doctor nurse treatment decision patients activities essential provide gsk prescriber patients interests always strengthen dedicated medical insights specific diseases identification come first understand scientific capability appropriately engage symptoms diagnosis application important role play providing doctors hcps improve multichannel clinical trial data medication dosage information medicines capabilities including use digital administration effectively expected clearly transparently technologies provide appropriate appropriately communicate benefits without perception conflict interest information products disease areas risks medicines help meet conveniently hcps also support patient needs fair balanced objective medical education hcps provision independent educational grantsnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report sales mandate pharmaceutical company put needs patients customers first putting focus patient one core values marketing heart sales marketing approach experiences last two years commitment usa suggest patientfocused putting patient first approach significantly improved continue drive valuesbased approach sales marketing practices across world interests customer interactions satisfaction rates possible pharmaceutical incentivising sales teams consumers patients core gsks us pharmaceutical business company improve sales asking knowledgeable ever sales teams stop focusing much raised bar gsk global code practice promotion directtoconsumer marketing sell start focusing industry customer interactions ensures prescription medicines sell believe gsks scientific engagement external advertise prescription medicines listen customers figure communities marketing directly consumers new zealand sales representatives lots address needs products driven values code usa directtoconsumer dtc stories patient first bring right gsk resources applies sales marketing employees advertising prescription medicines philosophy changed conversations help improve patient care says jacqueline well third parties acting behalf permitted markets customers helped establish trust carsanaro vp medical centre requires promotions accurate company customer satisfaction sales team serve hospitals dtc advertising usa governed promotional activity clearly surveys shown indeed clinics high satisfaction ratings dtc communications policy based identified outperformed best competitor customers increased phrma guiding principles competitor average delivering value result teams exceptional work gsk led industry first direct consumer advertisements customers deliver customerfocused solutions pharmaceutical company decouple reward prescription medicines dtc us sales representatives advertising usa reviewed legal number prescriptions issued focusing regulatory medical specialists new instead demonstration values dtc television advertisements focus patient see case study submitted us food drug administration fda review begin roll comment prior broadcast approach global basis implement us pharmaceutical business new global compensation programme receive notice violation warning individual sales targets letters fda advertising instead gsks sales professionals promotion products work directly prescribing healthcare professionals evaluated rewarded technical knowledge quality service deliver support improved patient care overall performance gsks business new compensation system rolled phased approach across emap japan europe intent countries gsk operates within areas move approach january note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report manufacturing efficient responsible manufacturing supply critical enable us get highquality products patients consumers right place supply right time zero accidents zero defects zero audit teams around world manage supplier ehs audits commitment waste significantly expanding regularly assess quality existing potential suppliers dedicated quality teams around performance suppliers continue ensure interests safety patients consumers paramount importance way world reinforce commitment deliver materials active pharmaceutical ingredients americas design undertake clinical trials product highquality products patients finished products key europe quality assurance monitoring reporting consumers across manufacturing suppliers assessed using asia adverse events ongoing product usage network invested around million gms quality risk model specifically africa holistic approach reduce environmental impacts created purpose also conduct total number many improvements bringing audits suppliers specifically ethical audits year produce four billion packs additional business benefits example environmental health safety ehs medicine consumer healthcare number types supplier audited ehs improving efficiency increasing governance risk management products million doses vaccines existing potential suppliers manufacturing capacity assess suppliers first selection supply countries subsequently also audit high risk type supplier americas europe asia total suppliers integral process also working sustainability expect uphold high areas completion every audit primary raw materials programmes suppliers agree improvement plan suppliers intermediates standards set asked largest pharmaceutical ingredients address areas concern verify materials suppliers highest spend contract manufacturing year spend around billion plans implemented satisfactorily pharmaceutical goods services categories disclose sustainability significant gaps identified formulations manufacturers accounting footprint carbon water waste energy may suspend terminate work consumer healthcare use identify priority areas spend ingredients materials supplier decide work supplier audit counted single audit even buy feed network gsk improvement across supply chain potential new supplier multiple siteslocations included manufacturing sites countries supplier standards part work assess manage increased resources provide around external spend third party code conduct commits gsks impacts human rights see extensive ehs riskbased auditing suppliers provide us finished network approved external suppliers working standardise across supply base including external partfinished products business partners uphold gsks approach procurement across suppliers third party distributors values sets standards ethical geographies business units moving endtoend supply conducted internal ehs audits conduct antibribery fair labour including simplify existing controls chain model pharmaceutical vaccine involving site visits supplier facilities protection human rights environment effectively identify manage human consumer healthcare products also commissioned specialist insurance health safety management quality rights risks supply chain standardise improve controls company review risks supply gsk control suspected breaches across entire supply chain also member pharmaceutical supply reported speak programme manufacturing operations procuring chain initiative psci open third parties see raw materials quality controls collaborate pharmaceutical packaging transport logistics companies audit suppliers human risks supply chain integrated involved delivering products rights labour practices well overall risk management customers part transition across ehs performance psci audited compliance process network pharmaceutical six suppliers relevant gsk supply consumer healthcare manufacturing sites chain driving progress towards visionnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report manufacturing supply continued payment terms anticounterfeiting comprehensive global anticounterfeiting work closely law enforcement greatly value relationships global study issue strategy combines use technology regulatory agencies combat counterfeiters many suppliers understand difficult quantify prevalence analysis investigations appropriate legal significant seizures pressures cash flow financing faced counterfeit drugs little doubt enforcement action interactions result cooperation china smaller companies following change problem widespread poses law enforcement customs counterfeits example authorities conducted raids six standard payment terms suppliers serious threat patient consumer gsk products discovered counterfeiting factories resulted uk usa offered health well business threat gsk consumer patient complaints convictions counterfeiting variety review payment terms smaller pharmaceutical companies investigations raids conducted law medicines including contac nt cold suppliers identified micro small enforcement regulatory agencies treatment fenbid pain reliever counterfeit drugs range precise medium size enterprises europe diverse well investigators acting behalf gsk pakistan three counterfeiters arrested replicas original product products suppliers usa also offer range analysis shown large quantity counterfeit ventolin legitimate active ingredients supply chain finance options counterfeited gsk products include syrup used treating asthma seized supported appropriate quality uk us suppliers sensodyne aquafresh toothpastes raid pakistan provincial control testing monitoring may medicines panadol dolex drug authorities several companies taken include impurities particulates augmentin ventolin opportunities already planning microorganisms patients consuming increase number increased communications well counterfeits risks range lack introduced range anti reported counterfeit incidents dedicated small business hotline make treatment protection actual harm counterfeiting measures product compared previous years smaller suppliers aware caused product codes used consumers africa accounted increase successful support available verify authenticity via simple text message raid actions pakistan seizures discoveries counterfeit grandpa china largest volumes headache powder south africa counterfeits manufactured include supplier diversity unique serial number product package products essential diversity within workforce among engage global network diverse drug list enable electronic monitoring suppliers supports continuous suppliers participating relevant purpose patient safety looking innovation business built conferences initiatives extend additional products exposing us new perspectives fresh us national minority supplier programme running next four years ideas sourcing underrepresented development councils global link initiative groups small businesses women minority supplier diversity uk minorities also supports economic gsk board member organisation gsk anticounterfeiting activity development regulatory requirement develops links global usa total us businesses ethnic minority businesses expenditure diverse small number reported businesses increase cases counterfeit number raids number arrests note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report public policy contribute debate global health challenges issues advocating policy environment protects interest patients patient advocacy around world supporting business calling g governments partnering european governments lobbying expenditure commitment acknowledge potential greater help reduce impact fiscal austerity costs associated lobbying information exchange data measures continued patient access eu institutions range demonstrate gsk interactions patient transparency among tax authorities lifesaving gsk medicines outlined advocacy groups political stakeholders conducted appropriately ethically transparently demonstrating effectiveness european transparency register figure working governments increase national international tax rules includes running brussels advocacy committed ensuring coordination simplify pharmaceutical office salaries external events travel interactions political stakeholders working us policymakers registration improve registration accommodation consulting costs patient advocacy groups conducted implementation affordable care act processes china russia taiwan educational materials also takes appropriately ethically transparently support provision medicines ukraine address challenge account proportion employee time reviewed published vaccines new federal regional disparity access medicines spent representing gsks interests criteria use work public policy staterun health insurance marketplaces eu institutions excludes trade association trade association membership groups assessed medicaid insurance programmes membership fees gsk member many trade industry memberships renewed criteria lowincome americans additionally associations primarily represent result withdrew launched new collaborative platform usa spent federal pharmaceutical consumer product american legislative exchange council healthy communities healthy lobbying activities see us federal vaccine businesses national regional alec remain committed working america identify advocate lobbying register includes costs international levels membership public policy groups aligned solutions promote collaboration salaries benefits employees groups support efficiency values priorities also agreed improve access high quality healthcare registered lobby us government effectiveness public policy work new standard operating procedures advance innovation includes use lobbying consultants support see website full list govern work public policy groups patientcentred medical homes lobbying contacts planning activities train employees comprehensive medication management political contributions research running gsk washington coordinated care models improve dc government affairs office support staff make corporate political key public policy engagements quality care patients reduce portion trade association fees contributions included overall healthcare costs associated federal lobbying employee pacs supporting immunisation programmes partnering us department us employees choose make around world partnership health human services personal political contributions gavi alliance working partners biomedical advanced research gsk employee political action committee innovative medicines initiative development authority texas pac allows eligible employees address related rd manufacturing university open influenza vaccines provide financial support political groups access challenges exploring new manufacturing facility unprecedented accordance federal election financing mechanisms vaccination public health collaboration ensure campaign act gsk employees rapid national vaccine response working governments pac contributed event influenza pandemic stakeholders primarily europe republican candidates usa address growing threat democratic candidates running state antimicrobial resistance see federal offices encouraging greater investment rd supporting activities promote appropriate use antibacterialsnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report public policy patient advocacy continued patient advocacy example european patient advocacy health also facilitated pals germany japan engage patient groups nonprofit advisory board hab made romania since member european patients organisations founded patients caregivers european patient groups patient advocates countries academy therapeutic innovation family members health professionals opportunity gsk employees gain participated pals events around contributing expertise staff time funding help improve understanding patient patient group insight policies world develop indepth training courses needs illnesses patient groups engage initiatives brings voice patient support qualitative research help patients healthcare providers governments heart organisation helps us read online european countries become media patients promote improved understand meet patient needs effective advocates research treatment healthcare services also topics covered included work publish detail online key campaign issues affect patients development new medicines antibiotics adaptive licensing clinical data issues including caregivers lives carry research working national coalition transparency plans working gsk antibribery corruption causes potential treatments patients chronic diseases patient groups emerging markets asia handbook specific conditions pacific region partnership save pharmaceutical companies organise gsk antibribery corruption children see national forum patient associations guidelines third parties relationship patient groups guides rd helps ensure romania activity included gsk employees relevant third cloning technologies stem patient opinions heard see national information campaign patients parties work patient groups must cell research roundtables doctors launch recognise stakeholders want follow guidelines standard disclosure clinical trial information telephone helpline patients understand nature support operating procedures example get information rights care welfare treatment animals patient groups publish information limit amount funding online work patient groups diseaserelated questions provide patient groups overall role transgenic animals biomedical research europe asia pacific emerging markets iowa usa collaborating funding require relationships well information support patient groups must never linked use nonhuman primates nhps partnership better health network patient groups working globally including promotion products discovery development healthcare providers advocates details funding received publish medicines vaccines consumers dedicated lowering cost patient advocacy leaders summits information online work including care prevention access counterfeiting healthcare products patient advocacy leaders summits funding details patient groups innovation collaboration helps pharmacovigilance pals uniting patient advocates europe us canada australia asia pacific educate policymakers public ten years across different criteria working public emerging markets need invest preventing chronic therapeutic areas discuss health policy policy groups diseases affecting usa including provide funding patient groups develop new skills explore ways global code practice promotion diabetes heart disease lung disease form unrestricted grants support expand influence usa customer interactions daytoday running organisation uniting community initiative national pals event washington dc code conduct corporate partners fees defined six regional pals across country originated patient advocacy clinical trials developing world projects support also includes focused patient advocates role leaders summits focus healthy development educational materials implementing healthcare reform ageing cancer training staff collaboration implications different health insurance disease awareness prevention projects marketplaces well issue medicaid expansion statesnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report approach tax businesses increasingly activities located uk transparency tax authorities tax havens challenged ensure contribute currently increasing investment gsk supports calls multinationals engage artificial tax tax system societies addition corporation tax profits provide greater transparency tax arrangements without business operate provide information generated employment value authorities participated commercial substance policy tax management principles policies activities create subject consultations proposed country use locations number uk taxes including indirect country reporting disclosure tax substantial business presence understand responsibility pay tax employment taxes authorities announced substantial local business presence appropriate amount tax organisation economic cooperation vast majority territories time responsibility weve continued programme developments oecd base erosion operate whether business offices shareholders financially efficient centralising pharmaceutical intellectual profit shifting action plan july sales force manufacturing rd facilities deliver sustainable tax rate fully property product inventory ownership local distribution products support efforts ensure companies uk started international tax framework contribute economic development appropriately transparent change ip ownership structure multinational business believe create shared value region tax affairs managed made possible introduction new contribute debate regarding business patent box tax rules uk government global tax policy particular contribution substantial came force making current debate whether existing internal processes business employment presence many uk attractive place locate ip international tax law framework set robust internal policies processes countries around globe pay investment decision centralise ip oecd fit purposes todays training compliance programmes significant amount tax including fund rd uk means environment gsk supports work ensure alignment across corporation business taxes medium term expect pay oecd commissioned supported business meet tax obligations well tax associated employees corporation tax uk g base erosion profit audit risk committee example since formation gsk value generate sales shifting paper committed board responsible approving paid billion pipeline products created providing relevant business input tax strategy management corporation tax globally uk subject uk tax transfer pricing agreement tax payer tax global corporation tax charge authority appropriate transfer pricing methodology relationship tax authorities line current oecd guidelines core profits approximately certain transactions fixed period time gsk seeks maintain open positive base transfer pricing policy arms billion equating group tax rate relationships governments tax length principle support transfer underlying principle transfer pricing even profits means corporate though two companies within group authorities worldwide welcome prices economic analysis reports act independent enterprises tax due core profits around world constructive debate taxation policy worldwide nature operations means companies must appropriately amounted nearly one quarter total rewarded assets employ risks entered bilateral advance pricing means rd manufacturing core profit made year assume entering intragroup transactions agreement irs hmrc operations centred number key ensure profits generated taxed countries details corporate tax charges started bilateral discussions locations consequence value arises appropriate reward year set annual report considered reward would obtained tax authorities number crossborder supply routes necessary third party known arms length principle countries intention agreeing ensure supplies medicines numerous pay considerable amount tax advance pricing agreements endmarkets complex uk given group sales agreements provide longterm certainty generated country tax authorities gsk significant proportion global corporate tax treatment gsks business functions rd manufacturingnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report people focus people essential success focus building individual capabilities aim alicia electrical engineering graduate one gsks specialist support empower graduate schemes future talent essential business success best run several schemes support talented employees like alicia early careers read section people overview setting standard employee healthcare talent leadership development inclusion diversity engaging people health safety wellbeing performance reward recognition note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report people overview creating strong leaders offering glance talent leadership development health safety wellbeing individual development opportunities reached leaders countries reduced injury illness rates rewarding people based coaching programmes deliver well achieve strengthen leadership capabilities motivating employees excel put internal perspective see values heart every decision designed new see make want feel proud performance system connect work company work difference make individual performance reward align collective efforts gsk living mission starts within improving health wellbeing deliver strategy heart health safety wellbeing employees helping people build system individual talent leadership development equipped employees tools energy levels resilience productivity leadership expectations increased number employees cope workload stress energy introducing unrivalled preventive year completing voluntary assignments resilience training since guide healthcare benefits employees nongovernment organisations nonprofit families worldwide aligned values organisations pulse see inclusive employer want ensure claire thomas people feel valued thrive svp human resources gsk see individuals inspired work together internal perspective help us achieve mission whatever inclusion diversity background w hen look increased proportion women performance reward recognition management compare attended began roll preventive healthcare energy performance realise see benefits partnership prevention programme available totally different person employees families worldwide better leader husband father way look see take care health first role model others inclusion diversity performance reward recognition look leader graduation first project search launched gsk expectations part willing listen want cohort subsequent recruitment new performance system better link next group students employee reward values follow say see see richard lewis immunology rare diseases gsknote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report setting standard employee healthcare gsks partnership screenings low engaged resilient prevention pp programme cost multinational workforce giving setting standard company employees opportunity employee healthcare scale improve protect health piloted matter job programme ecuador work want services even ghana nigeria employees greater need romania pp access healthcare working countries offer benefitseligible need fit preventive healthcare may employees families healthy providing access unavailable access access preventive preventive healthcare limited health services reinforcing efforts vaccinations cancer maintain motivatednote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report talent leadership attract retain talented people investing training development tailored individuals needs builds development employees strengths managers leaders graduate recruitment globally want talented highpotential provide managers skills employees become next leaders engage teams motivate individuals gsk programmes aim identify perform best accelerate progression strongest leadership programmes aim talent example flagship develop future leaders around world global mba programme esprit esprit participants completed series leaders completed rotations across countries finance leading delivery programme helps rd medical commercial units middlelevel managers translate strategic enabling build skills ambition business meaningful knowledge different markets regions action also enrolled leaders onto see case study leading business designed graduate senior leader develop capabilities managing four years esprit business function people new management positions launched target management essentials teaches dipal joined gsk post core management skills early careers graduate programme offer wide range opportunities four years later moved coaching one key ways help including internships industrial placements new role european marketing director people build skills strengthen apprenticeships graduate schemes completing esprit mba leadership capabilities made global entry level students programmes help programme helped achieve focus gsk programmes us develop skills business requires fundamentals leadership future intake graduates onto fouryear programme enabled provides training leaders managers development programmes around world gain broad range experience working coaching effective leaders since continued rise pharmaceutical business leaders trained making progress australia vaccines business job plus coaches towards global target recruit thailand vaccines centre high potential executives received coaching graduates year see chart excellence belgium fasttracked executive coaches total uk apprentices joined gsk learning development gave reached leaders committed recruiting skills knowledge confidence coaching programmes apprentices next two years take new role senior leadernote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report talent leadership development continued development community involvement swapped job director marketing france work commitment care international bangladesh extend volunteering opportunities bring develop communication strategy positive change communities global health providing individual development care gsks reinvestment initiative help reduce maternal pulse volunteer partnership programme gives employees child mortality remote parts asia opportunity work fulltime three feel biggest achievement six months nonprofit organisation develop staff capacity charity help address global healthcare implement communication activities challenges developing leadership skills employees volunteered departure seen organisations including save impact reinvestment work children part new global least developed countries feel partnership charity see really proud work gsk employees completed pulse assignments found isabelle likely change roles less gsk france likely leave gsk compared overall employees completing pulse employee pulse programme made us employee population countries development programmes surveys conducted capable organisation stronger partners indicated nonprofit faster smarter gsk employees organisations something know helping save differently even six months pulse volunteers left assignments greatly improve lives people find pulse volunteering around world website see volunteering gsk ross comstock director santa barbara us ngo working pulse volunteers since note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report inclusion aim create inclusive workplace attract retain talented people backgrounds cultures diversity maintain longstanding relationship women management positions project search improves young commitment disability organisations peoples employability sermes spain business continue promote inclusion diversity globally disability forum uk svp vp gsk participation project search initiative director students aged gender diversity also helping young people manager learning disabilities gsks focus enable gender diversity learning disabilities make transition total completed work experience gsk management senior roles education work see case study help transition education introduced targeted individual work part support group coaching sponsorship cultural ethnic diversity project search promote cultural diversity emerging diverse talent piloted new online resource help onetoone support gsk invite employees join dialogue sessions develop employees awareness cultural employees volunteered mentors discuss address hidden barriers differences build skills needed helped students build skills could hinder gender diversity interact effectively colleagues around completed three tenweek rotations percentage women world application launched variety roles including reception management continued rise see chart globally procurement hospitality security women represent corporate three interns since secured executive team exceeded value broad spectrum experiences parttime jobs working facilities goal achieve least female board employees different parts world management retail one representation five female bring business people taken full time local council employ emerging markets asia pacific nonexecutive directors making japan represent total overwhelmed much board gsk ranked joint third workforce six nationalities represented students grown confidence female ftse board report corporate executive team board ability short time says lorna study womens representation project search tutor gsk boards uks top companies monitor benchmark proportion students positivity disability ethnic minorities workforce commitment work become real want make sure people local country level industry averages inspiration many employees national population countries disabilities access career uk usa report opportunities gsk bringing valuable locally engage groups talent expertise business representing diverse communities disability global focus gsk establishing global disability council agree priority areas set objectives monitor progressnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report engaging engaging employees mission strategy gives clear sense purpose enables understand actions contribute people success business ceo members corporate introduced regular interim orange united employee engagement executive team cet deliver live broadcasts surveys individual business units messages keep employees updated functions covering around companys progress towards employees year results showed first time asked strategy commitments encourage businesses made significant employees countries work employees regular interaction improvements team leader effectiveness together support single cause leaders provide leaders priority area improvement based set ambitious goal raise resources need respond effectively survey results million save children part senior leaders reporting global partnership charity cet received communication approach restructuring see delighted training help engage effectively implemented second phase see enthusiastically people teams major change programme risen challenge marathon announced programme exercise sessions zumbathons listening responding employees focuses encouraging integrated dodgeball tournaments book bake engage people formally collaborative efficient ways working sales fundraising activities informally understand views across businesses advancing orange week alone raised almost working gsk improve technology reducing costs making massive contribution experience aware effect restructuring target employees aim achieve employees using organisational financial goals without new social networking tool ask questions eliminating positions redeploying raise issues promoting dialogue employees possible jobs lost colleagues around world levels result changes business company also enhanced intranet consult employees encourage interaction internal representatives offer compensation dialogue example enabling employees support outplacement volunteering post comments news features line local requirements employment part efforts engage motivate frequently ask employees participate legislation employee assistance people encourage get involved formal survey understand programme resilience training provide local projects support communities employer appreciate additional support see orange day volunteer programme taking time complete survey entitles employees one paid day responding feedback priority year volunteering launched since last full survey individual major fundraising initiative challenging business units developed action plans employees around world work together address several issues identified key raise million save children areas improvement training see case study leaders better coaches see supporting employees change better recognising individuals contributions see note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report health safety progressive healthcare company helping employees stay healthy wellbeing resilient productive priority brings mission life people reported nearmiss improve safety employees working leading causes reportable injury illnesses commitment incidents increase since manufacturing continued implement risk reduction initiatives c peo pti ln eu te go r oc wre ne p w ero fork ri mng ne n av hir eo lm n n dh ret sin ils iep nir te ws ay sau fer tm mv ae n ao g e mgl eo nb ta wl ill fad ce il l ar eh e sha alt rh na gn included upgrading protective guards stop manufacturing employees risk profiles best practices first foremost responsibility getting close machinery sites retaining focus health ensure physical harm comes operation reviewing respiratory safety site level also people work safety protective equipment reduce exposure fundamental part corporate culture expanded network health safety harmful airborne powders coordinators make sure safety recognise employees resilience programmes track also continued improve also affected wide variety ergonomic process safety across manufacturing factors workload stress two serious incidents slipstripsfalls personal lives efforts promote two employees received minor burns en ved n r ts sd u co hp e ar sa fiio ren ss eo x pp lr oe sv ie nt ae nr dio us moac toh ri n vee hry icle accidents employee wellbeing focus giving fire irvine uk maintenance contact sharp objects releases hazardous substances working people support need build worker verona italy suffered partial burns thermalchemical university sheffield uk energy levels cope stress finger amputation check developing fourday open access also going one step machinery required safety training course process safety covering reportable injury illness rate guard removed per hours worked multinational employer committing fire explosion risk prevention provide comprehensive preventive healthcare targeting specific safety risks strategies specifically pharmaceutical benefits employees families many countries driving represents one consumer healthcare industries worldwide partnership biggest safety risks employees course form part universitys prevention programme see performance following pilot launched driver masters science process safety reward recognition safety training programme countries loss prevention embedding culture zero harm employees completed training read online achieve goal zero harm significant impact gsk australia instance employees focus preventing experienced reduction publish detail online key incidents occur targeting businessrelated driving incidents first issues including training awareness activities key risks year implementing programme safe driving use machinery hazardous chemical management deliver training three achieved reduction injury emerging markets tablets smart gsk reach illness rate compared also phones employees also invite family worked increase reporting nearmiss member training free charge target incidents help us address specific safety helping extend safety home life issues incident occurs share knowledge across business help prevent serious incidents elsewhere resultnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report health safety wellbeing continued health safety data summary impact energy resilience training type total number countries impact training employees hours worked million energy reported increases energy fatalities performance months programme ep calendar days lost likely make improvements lifestyle especially diet report number injuries illnesses lost time excellent health losttime injury illness rate resilience improvement recovery energy personal calendar days lost rate resilience significant reduction perceived reportable injury illness rate teambased workplace pressures better able cope number nearmiss incidents per hours worked data restated actual data available replace estimated data reported previously excludes data number commercial operations business units nearmiss incidents reported globally data relates results pilot project global manufacturing supply data assured bv see energised resilient employees objective enable employees lead introduced renew refuel managing resilience oneday believe levels energy good healthier happier lives work energy coaching programmes workshop teaches leaders indicator people feel perform home participants agree works energy resilience portfolio build teams skills confidence supporting employees manage said performance work launched several new courses including reduce stress lead increase energy levels helping improved completing ep training mental illness time moment online course cope better workloads end total encourages employees find time take also scaledup employee stress within outside workplace employees countries participated short breaks working day assistance programme eap enabling energy performance ep energy resilience training since increase concentration focus employees worldwide access practical programme includes personal introduced advice information counselling energising educational initiative teambased workshops training significant impact see quote results confidential helpline website provides advice boost courses help employees remain research impact ep energy eating regular healthy meals focused energised productive published peerreviewed journalnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report performance reward gsk people achieve results important achieve incentivising behaviour consistent values priority recognition way evaluate recognise reward performance putting values heart extending preventive healthcare benefits b efore introduction pp performance reward employees wasnt wide awareness introducing new putting values practice importance vaccines performance system ensure introducing competitive benefits packages employees understand expected including preventive healthcare benefits medical checkups example help set clear objectives employees families unmatched know help deliver strategy create multinational company vaccine help protect clear link values groundbreaking partnership cervical cancer general health employees rewarded gsk expectations clearly outlining way prevention pp programme offers screenings also made realise benefitseligible employees family expect employees work deliver need cautious members access preventive strategy also introduced new health services little cost date glucose cholesterol levels fivepoint rating scale enable us employees family members make certain lifestyle changes provide clearer feedback employee countries including ecuador ghana performance help differentiate immediately pp service nigeria romania middle east best performers exist may taken receiving pp benefits plan performance system includes new implement pp globally part health issues consideration global bonus structure pilot ran also focused even might employees bonus aligned encouraging employees able afford treatment achievement individual objectives exercise improve diet recognising exceptional scientists based business area since developed global physical fitness rhoda results greater emphasis individual programme launched employee ghana business founded innovation performance help employees pp see case study want scientists know understand personally contribute value important contribution delivery strategy living pensions benefits make exceptional science award values links reward benefits total reward packages programme offers rewards company also introducing new vary country country always shares scientists made compensation system sales teams designed attractive competitive outstanding contribution discovery rewards patientfocused behaviours local market include shares development new medicines rather amount sales see savings plans health benefits eligible annual share senior people pensions see annual report grants programme designed disincentivise unethical working practices emphasise scientific research using clawback mechanism allows development linked success us recover performancerelated pay business awarded grants see annual report total since executive paynote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report planet focus working hard reduce environmental footprint even grow business extend benefits gsk adina pharmacy manager london one pharmacies gsk products patients customers running complete cycle inhaler recycling scheme complete cycle around world encourages patients return old inhalers participating pharmacy recycled helping reduce waste carbon emissions read section planet overview taking scientific approach sustainability carbon water waste managing impacts engagement data summary summary assurance statement note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report planet overview committed managing glance carbon reducing environmental impacts operations products across scope emissions excluding raw materials increased across value chain lifecycle stakeholders expect us due strong sales hfa propellantbased longterm success business carbon inhalers increased since depends ensure continue scope carbon emissions deliver high quality products patients operations grew slightly see consumers future must although remain lower internal perspective protect natural resources need make today baseline water w e focused reducing used less water resources already becoming operations emissions energy water use scarcer expensive effects see throughout supply chain climate change water scarcity could mapped water use across value chain benefits environment threaten improvements global production raw materials accounts health medicines vaccines external perspective estimated total water footprint also reduces waste cost consumer products helping deliver operations represent reinvest savings applaud gsks approach innovation improving access set ambitious goals reduce minimising environmental see carbon water waste across value medicines footprint first chain sourcing raw materials water impacts labs company worldwide announce became first company awarded roger connor president global manufacturing supply factories use disposal new respiratory drugs global certification carbon trusts gsk products patients consumers launched dry powder water standard recognition using resources efficiently yearonyear reductions formulations less collaborating others tackle operational water use globally challenges reduce costs global warming enhance competitiveness potential hfa inhalers see reducing water engagement year year however gsk must maintain reviewed carbon waste water waste data momentum reach generated waste due suppliers ambitious carbon targets business growth achieved better understand reduction compared environmental impacts ashley woodcock obe supply chain consultant respiratory physician university see hospital south manchester see shared nobel peace prize ipcc waste al gore achieved zero waste landfill sites see note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report taking scientific approach sustainability sourcing raw materials jurong singapore teams biotreating waste world innovative complex energy eight facilities recovering energy process significantly intensive chemical processes produce active ingredients produced achieved zero cut carbon emissions involved transforming implementing holistic waste landfill third reducing cooling products accounts improvement plans year running requirements well around half value chain bringing significant cut water use producing less organic waste carbon footprint environmental benefits carbon emissions many improvements cost reductions since last five years making take time using infrastructure investments also making changes implement across innovative technology included installing chemical processes eight sites already reduce environmental biogas plant irvine example cut energy use co impacts associated uk combined heat investing new process emissions water use manufacturing active power facility worthing facility quality road waste landfill pharmaceutical ingredients uk photo oxidation singapore uses since substances system waste treatment enzymes manufacturing drugs treat prevent singapore site amoxicillin one illness following trials cork ireland widely prescribed antibioticsnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report carbon set ambitious targets achieve carbon neutral value chain reducing operational carbon emissions engaging suppliers consumers cut emissions associated sourcing raw materials using products understanding value chain carbon footprint raw materials gsks operations logistics use products disposal working suppliers reduce investing technology efficiency aim minimise carbon emissions products particularly established inhaler impacts associated sourcing raw measures renewable energy reduce transporting products propellantbased inhalers generate recycling programme engage materials well exploring ways use carbon emissions energy use customers using sea freight rather carbon emissions use patients reduce emissions associated resources efficiently products operations also generate carbon emissions air redesigning packaging patients consumers disposal products production propellantbased make transportation efficient inhalers employee travel tonnes coe per annum tonnes coe per annum tonnes coe per annum tonnes coe per annum tonnes coe per annum use metered energy tonnes co e per annum tonnes co e per annum dose inhalers hfa process use tonnes co e per annum emissions tonnes co e per annum products business travel tonnes co e per annum total emissions sales force tonnes co e per annum tonnes coe per annum estimatenote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report carbon continued performance operational impacts vaccines site tuas singapore external recognition partnerships reducing energy use carbon installed trigeneration plant uses achievements cutting carbon commitment emissions associated generating waste energy generated production emissions across value chain energy purchase important electricity heating cooling recognised cdp notforprofit reduce overall carbon footprint focus programme cut improved energy efficiency organisation providing global framework vs carbon neutral value chain environmental impacts investing saved around million year measure companies impacts energyefficient technologies sites achievements recognised environment gsk healthcare scope emissions increasing use renewable energy singapore energy efficiency national company listed global climate operational boundaries example facility irvine uk partnership awards best practice change report ranked million tonnes co e slight increase introducing series alternative category improving efficiency cdp performance leadership index compared reduction energy sources including million measures prevented sites total cdp disclosure leadership index since investments made wind turbine anaerobic digester energy consumption rising even performance quality start deliver carbon use waste site generate production volumes increased reporting cdp submission emission reductions see chart energy combined heat power plant publicly available cdp website continue identify opportunities installed already reducing scope emissions profitable energy carbon emissions year also received cost producing antibiotics site associated logistics business reductions sites around world carbon trusts best continuing carbon annually travel patients use hfa propellant example increased reduction award yearonyear based inhalers increased compared amount biomass used fuel replacing reductions emissions associated overall increase since coal two sites india operations followed global see chart tackling scope certification carbon trust standard emissions continues challenge scope ghg emissions scope ghg emissions renew especially product sales continue increase particular looking continue work association longterm options reduce carbon british pharmaceutical industry emissions related ventolin whilst still uk national health service sustainable meeting patient needs preferences development unit following development carbon footprinting product impacts guidelines pharmaceutical sector using carbon footprint analyses together launched tool help top products identify companies calculate carbon footprint make effective reductions tablet medicines distributed emissions associated blister packs products sourcing raw materials manufacturing use disposal gsk also member un caring example reduced climate programme initiative amount propellant hfaa powerful gas fuel purchased materials increasing businesses role addressing greenhouse gas used purge aerosol cans e pl oc pt eri lic ai nty e se sa iom ns manufacture inhalers p br uo sd inu ec st l trg ai vs eti lc bs air climate change air filled ventolin sales force travel propellant emissions use inhalers emissions use products disposal productsnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report water reduce overall water impact associated products working reduce suppliers consumers water use well targeting reductions operations analysis help us develop effective year conduct highlevel rolled improvement programmes commitment programmes meet commitment assessment water use global pakistan kenya followed cut water impact across operations using world business uk india reduce water impact across value value chain example already council sustainable developments starting see results example chain vs begun efforts address consumer water global water tool help us identify horlicks manufacturing plant slough mapping water footprint across use using toothpaste brands save water respond potential uk second biggest value chain launch turn tap campaigns italy water risks four countries belgium india consumer water reduced water use million cubic metres puerto rico encourages people uk usa account use since water year operations research use less water brushing teeth total water use also use external recognition partnerships laboratories manufacturing facilities wbcsd tool information local reducing water use operations working ngos develop offices accounts watersheds identify operations areas achieved reduction longterm strategy address issues total water footprint remaining water scarcity water consumption operations water scarcity water quality footprint relates water used keeping us track meet target developed systematic approach regulatory risk help reduce potential rest value chain see chart cut operational water use find opportunities save water sites impacts communities builds reduce overall water impact need baseline high volume use consumption commitments made un ceo explore ways reduce suppliers increasing areas water scarce water mandate initiative helps consumers water use companies develop implement working external experts gain better sustainable water practices gsk understanding water footprint signed biggest impacts estimated gsk became first company total water footprint associated products million production net water consumption operations awarded global certification carbon trusts water standard recognition raw materials used make products estimated value chain water footprint yearonyear reductions water use account vast majority footprint target way manage measure water across second biggest contributor million cubic metres global operations also respond consumer use products see chart cdp water disclosure project year initial highlevel assessment helped latest submission publicly available us determine need estimated value chain water footprint cdp website accurately investigate water consumption value chain including water use agricultural supply chains milk malt wheat glucose goes products water use water used produce raw materials toothpaste consumers also water used generate purchased energy water used operations starting understand world water used consumers patients using products water use high impact environment communities based analysis data latest version conversion factors water used produce raw materials water used generate purchased energy water used operations water used consumers patients using productsnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report waste goal halve operational waste adopting four simple steps eliminate reuse recycle generate energy waste order priority operational waste read online commitment target commitment reduce operational waste publish detail online key vs total waste generated issues including thousand tonnes generated waste climate change result business growth waste landfill hazardous chemical management year sent total thousand tonnes waste landfill sites genetically modified micro organisms achieved zero waste landfill changed way report waste longer include solvent waste recycled reused site environment health safety ehs aim halve part total waste generated gsk reach operational waste compared zero waste landfill breathing life old inhalers gsk convention biological diversity recognise business continues grow need continue efforts around million inhalers prevents remaining propellant used gsk public policy nanotechnology reduce waste sites generate used uk every year go inhalers released greenhouse identified sites responsible rubbish bin end going landfill gases collect crushing ozone depletion metereddose generating majority waste cans recover aluminium inhalers asthma gsks inhaler recycling programme increased focus pharmaceuticals environment complete cycle encourages patients established uk cities developing implementing improvements return old inhalers participating usa programme also impact climate change health high impact manufacturing sites pharmacies sent back set several markets including addition established programme us recycled australia chile czech republic use ozone depleting substances reduce waste ancillary plant equipment reduce waste sent landfill also hungary efforts cut waste landfill include reusing refrigerated packaging shipping vaccines insulation material construction industry saves tonnes waste year previously paid send landfill sites barnard castle montrose uk set centralised points collection waste using smaller bins frequently emptied encourage employees use regularlynote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report managing manage range important issues reduce overall environmental impact addition priority focus areas carbon impacts water waste sustainable supply lines medicines encourage biodiversity environmental remediation use lowerimpact alternatives gsk directly involved bioprospecting take responsibility removing pollution commitment process discovering new products contaminants soil surface also investing research come biological resources ground water facilities used build sustainable supply lines nutrition portfolio sustainable chemistry construction plants animals source previously disposal sites waste work local farmers improve agricultural carbon neutral sustainable chemistry practices improve yields competitiveness number compounds derived management companies used laboratory began part million livelihoods biological resources take spent million remediation collaboration university responsibility ensuring work compared us million began working dairy supplier nottingham uk also pledged obtained legitimately used way sole part responsibility india develop secure supply locally year establish intended also support efforts remediation sites globally produced whey protein milk make centre excellence sustainable conserve biological diversity horlicks benefit supplier chemistry paulo brazil advance compliance fines convention biological diversity bonn improving agricultural practices help us share knowledge subject received three environmental guidelines nagoya protocol reduce environmental footprint researchers brazil uk fines totalling fines sourcing whey protein local singapore funding research packaging late submission report fuel supplier india aim increase green sustainable manufacturing also working reduce oil purchased sites pennsylvania amount locally produced whey protein part partnership singapore environmental impact packaging usa improper labelling empty road use within product range economic development board aim source wood fibre material tanker leaving site cork ireland horlicks second largest source carbon used paper packaging responsible discharge waste pharmaceuticals environment emissions milkbased products account sources repeated effluent limit tianjin china pharmaceuticals always completely half carbon footprint survey suppliers carton board absorbed broken body internal audits packaging corrugated packaging green chemistry residues find way audit operations make sure leaflet paper use information apply principles green chemistry environment excreted unused environmental risks impacts help us purchasing decisions producing many medicines medicines disposed consumers identified managed effectively sites help us reduce eliminate hazardous take issue seriously assess refrigerants selected audits based knowledge chemicals drug development environmental risk associated patients reduced inventory business modelling risk indicators discovery process see gsks position use products help ensure chlorofluorocarbon cfc refrigerants trends previous audit findings statement hazardous chemicals predicted concentrations exceed deplete ozone layer environmental health safety ehs management information safe levels also conduct support reportable levels inventory audits conducted team certified research area example eliminated within next five years iso environmental management lead green chemistry performance unit funded two students university remaining equipment containing cfcs auditors team audited sites cpu established researches york university cambridge becomes obsolete across different business units around ways replace hazardous unsustainable study impacts pharmaceuticals world site audits included review chemicals lower impact alternatives environment part phd research environmental management systems published specialist guide policy statement pharmaceuticals addition audited approach helps scientists understand environment available online governance processes around environmental impact different progression towards commitments reagents chemicals used produce carbon water waste information audits suppliers see note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report engagement meet ambitious commitments without engaging employees partners across value chain working others industry address global environmental challenges employees industry using range tools including online also communicate gsks sustainability social networks build employees message share experiences understanding environmental issues externally example head ways help address environmental sustainability guest collaboratively global network speaker cleanmed europe cdps sustainability advocates within gsk help ftse climate change report launch raise awareness among colleagues participating cleanmed europe gave us changes could make work opportunity engage healthcare home reduce environmental pharmaceutical professionals impacts recognise teams gather useful feedback performance made particularly valuable contribution environmental sustainability annual ceos environment health safety sustainability awards see case study suppliers started systematically gathering data suppliers carbon emissions water use waste building engagement suppliers using ecodesk publicly accessible database asked suppliers submit data help us better understand employees recognised discovering new process cuts carbon costs map suppliers sustainability performance end ceos environment health chemical use clinical trials suppliers contacted completed safety sustainability awards treatment fabry disease rare ecodesk profile recognised exceptional team genetic metabolic condition using using data prioritise biologists chemists working across synthetic biochemistry new process efforts reduce suppliers environmental rd manufacturing units working reduces manufacturing costs impacts example met granules collaboratively team discovered also cuts co e emissions around company supplies active developed new way manufacture ingredient use panadol together identified opportunities reduce energy use set collaborative programme realise savingsnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report data summary vs target scope emissions tonnes co e gas fuel electricity steam propellant emissions manufacture inhalers sales force travel emissions total scope emissions tonnes co e purchased materials product logistics business travel air propellant emissions use inhalers use products disposal products total total scope emissions tonnes co e water million water use operations waste tonne waste generated waste landfill mass efficiency weighted average new processes calendar year estimated data verified bureau veritas waste generated longer includes solvent waste recycled site reused processes mass efficiency measure amount raw materials required make new active pharmaceutical ingredient weighted account scale manufacture one low volume process transferred manufacturing leading lower efficiency figure remain track achieve target average performance five years longer report mass efficiency covers chemistry stages registered regulatory purposes complete manufacturing process established carbon footprint reduction strategy reduction target verified bvnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report summary assurance statement basis reporting bureau veritas summary opinion recommendations bureau veritas code ethics ensures external assurance independent assurance statement result verification conducted staff avoid conflict interest energy coe emissions data bureau veritas uk limited per scope work bureau maintain high ethical standards collected pharmaceuticals engaged gsk plc provide veritas opinion gsks ehs business activities consumer healthcare manufacturing independent assurance environment performance data gsks response assurance sites vaccines sites pharmaceuticals health safety ehs performance data provide fair summary ehsrelated pleased bureau vertitas findings consumer healthcare rd sites uk prepared gsk activities performance gsks established processes managing headquarters building offices plc objective bureau veritas work environment health safety data distribution centres water express opinion accuracy contain performance metrics committed continue improving hazardous nonhazardous waste data reliability ehs data information based established ultimate goal providing accurate collected manufacturing vaccines provide summary findings collection collation processes ehs data public website operations rd locations based deemed free significant full assurance statement found continue work toward materiality assessment collect error omission bias online includes details scope improving data accuracy emphasis nonhazardous waste wastewater data offices volatile organic compound work methodology findings data evidenced site level seen incorporating recommendations vocs reported sites recommendations improvement based wellestablished provided bureau veritas data manufacture pharmaceuticals contain rd implemented data management processes corporate responsibility report used summary scope methodology pilot plants use greenhouse gas underlying systems sites improve management assessment performance data environmental health safety programmes protocol calculations contained within ehs data table certain areas could lead continue working sites coe emissions energy use propellants associated data management processes refinement complete improve data submission including refrigerants involved detailed review integrity inclusion ehs data commercial providing comments explanation selected datasets aggregation use coe country factors electricity operations business units formal trends complete timely fashion checking processes corporate level published international energy definition structure quality control agency well sampling data back source process following anomalies detected read gsks full response assurance four gsk sites sites chosen consolidated ehs data detail sites selected review represent facilities significant may seen full assurance statement gsk businesses site specific audits environmental impact gsk operations conducted four sites data geographical spread statement independence impartiality verified back source special competence interviews senior ehs staff focus sites top contributors bureau veritas independent professional understand gsks objectives approach environmental emissions previous services company specialises quality data management year sites previously environmental health safety social visited prior years sites accountability years history difficulty submitting data timely manner assurance team extensive experience environmental social ethical health safety information systems processes london february note sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report governance commitment good governance transparent reporting reflects core values help us prioritise issues focus engage wide range engagement stakeholders understand matters governance audit assurance robust governance structure governance structure systems audit assurance department conducts place evaluate policies independent assessments adequacy programmes ensure approach effectiveness gsks management take corporate responsibility issues board significant risk areas including aspects appropriate boardlevel corporate chairman executive directors performance responsible business responsibility committee crc independent nonexecutive directors outcomes reported audit risk overall responsibility sits within committee line agreed assurance clear organisational structure plan includes assessing sample ensures accountability see graphic basis processes controls place comply laws regulations company corporate executive team cet standards throughout gsk headed sir andrew witty cet responsible managing audit team recommends strategies business overseeing internal improvement gsk managers develop audit risk remuneration nominations chief executive policies programmes action plans address causes committee committee committee officer noncompliance gaps internal corporate responsibility committee controls audit assurance tracks crc headed chairman sir corporate responsibility finance corporate administration corporate executive plans completion reports christopher gent including cet committee committee transactions team results senior management committee members boardlevel committee audit risk committee provides highlevel guidance oversight approach reviews read assurance internal audit performance progress risk management governance commitments see meets section annual report least four times year reports see annual report summary crc report including topics covered findings board annually crc meetings employee compensation human rights details audit risk committee board corporate governance level committee focuses key business risk areas gsk including nonfinancial reputational risks supported risk oversight compliance council roccnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report governance engagement continued stakeholder engagement g sk recognised market leader material issues resulting matrix issues shown regular dialogue stakeholders enables access medicines ask conducted formal materiality use inform approach us understand business may assessment prioritise issues reporting help us prioritise efforts pharmaceutical sector focus affect affected important business relation responsible business feedback helps us identify prioritise making access something stakeholders important issues develop responses commercial embedded business used findings stakeholder best interests society economically scalable gsk engagement conducted well shareholders gone last two years assess importance engage wide range specific issues different groups stakeholders daytoday vicki bakhshi stakeholders well looking fc asset management interactions customers engagement important issue business governments patient advocacy values strategy products groups see regular dialogue would like see gsk develop employees see suppliers context around economic development partners see investors linkages business also sought feedback ways youre corporate responsibility performance contributing building reporting formal engagement exercises including survey capacity rd training staff stakeholders worldwide series developing countries facetoface interviews two roundtable discussions opinion formers mark little uk usa bsr engagement found although focus access healthcare considered appropriate performance area strong highlight partnerships strive greater transparency way business clearer business case corporate responsibility activities show plan meet measure progress commitments used feedback strengthen communications reporting sredlohekats ot ecnatropmi materiality analysis output access healthcare ethical conduct transparency product innovation clinical trials conduct responsible sales marketing intellectual property rights lobbying advocacy practices product safety quality energy use climate change tax economic community investment diversity inclusion contribution animal research anticounterfeiting training development waste recycling privacy data security water use human rights labour ethical supplier standards talent attraction reward health safety wellbeing biodiversity security supply importance business successnote sb please keep coloured gradient buttons normal rollover actions please gsk corporate responsibility report report reporting report performance annually report part commitment open transparent business activities responsible business also covered annual report data coverage data report relates gsks global operations calendar year except otherwise stated data environment health safety sections independently verified bureau veritas brand names appearing italics throughout report trademarks owned andor licensed gsk associated companies reporting standards index global reporting initiative guidelines shows elements covered report signatory un global compact publish annual communication progress demonstrate uphold ten principles feedback counts welcome feedback responsible business performance reporting please contact us csrcontactgskcom also request receive regular updates progress